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Abstract
Lactoferrin (LF), a major protein present in milk, mucosal secretions and secondary granules of neutrophils, 
has been suggested to participate in host defense at mucosal surfaces and to mediate anti-inflammatory 
activities. A pepsin-derived fragment of LF has been shown to contain the antibacterial domain of the 
protein. Despite this proposed important dual capacity of LF at the mucosal membranes there are few in vivo 
studies to support these effects. Our aim was to investigate if anti-infectious or anti-inflammatory activities 
on mucosal surfaces could be mediated by perorally given LF or synthetic fragments of the antibacterial 
region of LF in experimental animal models, to gain insight into how LF mediates the anti-inflammatory 
activities in vitro, and to define the sequence in the antibacterial region of the LF molecule responsible for 
the antimicrobial activity.
Experimental mouse models of urinary tract infection (UTI) induced by E.coli 06K5 and dextran sulphate 
(DX)-induced acute colitis were used. The number of E.coli present in the urinary tract and the urinary and 
systemic inflammatory response (urinary leukocytes, urinary and systemic IL-6 levels) in mice with UTI 
were reduced by the LF treatment compared to the control group. Mice treated with LF peptide fragments 
(HLD1 and 2) also showed reduced numbers of bacteria in the kidneys. The perorally given LF was found to 
pass over to the circulation and urine. HLD2 mediated significant bactericidal activity against E.coli when 
tested in vitro in mouse urine. The damaging effects induced by DX exposure (presence of blood in the 
faeces, colon shortening, IL-lß serum levels, crypt score) were delayed or reduced in mice treated with LF 
or the peptides. The number of inflammatory cells present in the colon after 7 days of DX exposure (F4/80 
macrophages, CD4- and TNF-a-positive cells) was lower in the LF treated group compared to the control. 
LF also reduced shortening of the colon when given orally to animals with an already established 
inflammatory response as induced by two days of DX exposure. LF was shown to down-regulate the 
secretion of TNF-a, IL-lß, IL-6, IL-8 and IL-10 in monocytic cell lines (THP-1, Mono Mac 6) stimulated 
with LPS. The down regulation of the cytokines was reflected at the transcriptional level. Thus LPS-induced 
TNF-a-, IL-lß-, IL-6-, and IL-8 mRNA as shown by reversed transcription PCR were reduced as well. The 
known binding of LF to LPS could not explain the reduced cytokine mRNA expression and protein secretion 
since the effects were observed also when LF was added 30 min after the LPS to the cell assay. In addition, 
also IL-lß induced IL-6 secretion was down-regulated in the presence of LF. Moreover, LF was detected by 
immunocytochemistry in the cell nucleoli already after 30 min of incubation with the THP-1 cells and found 
by electromobility shift assay to decrease the binding of nuclear factor (NF)-kB to the TNF-a promoter. The 
antimicrobial activity against E.coli, S.aureus and C.albicans of synthetic peptides homologous to the 
surface exposed a-helix and ß-sheet region from the N-terminal end of human LF showed that a short region 
comprising 12-15 a.a. corresponding to the major part of the helix region were optimal for the killing activity 
against all three microorganisms. In addition certain amino acids such as cystein, and hydrophobic and 
positively charged amino acids in the 12-amino acid long peptide were found to be important for the 
expression of antimicrobial activity.
In summary, orally given LF can reduce infection and inflammation in a remote site such as the urinary tract, 
and mediates anti-inflammatory activities in the colon. This dual effect may partly reside in the antimicrobial 
region of the LF molecule, since synthetic fragments also provide similar activities. One possibly important 
mechanism of its anti-inflammatory effects is through the ability to down-regulate cytokine production via 
interference with the transcription factor NF-kB. The anti-infectious and anti-inflammatory activities of LF 
on mucosal surfaces is being utilized by the suckling child which obtains large amounts of LF via the 
maternal milk. However, therapeutic use of LF or its fragments may be possible in other fields of 
application.
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Abstract
Lactoferrin (LF), a major protein present in milk, mucosal secretions and secondary granules of 
neutrophils, has been suggested to participate in host defense at mucosal surfaces and to mediate anti­
inflammatory activities. A pepsin-derived fragment of LF has been shown to contain the antibacterial 
domain of the protein. Despite this proposed important dual capacity of LF at the mucosal membranes 
there are few in vivo studies to support these effects. Our aim was to investigate if anti-infectious or 
anti-inflammatory activities on mucosal surfaces could be mediated by perorally given LF or synthetic 
fragments of the antibacterial region of LF in experimental animal models, to gain insight into how LF 
mediates the anti-inflammatory activities in vitro, and to define the sequence in the antibacterial region 
of the LF molecule responsible for the antimicrobial activity.
Experimental mouse models of urinary tract infection (UTI) induced by E.coli 06K5 and dextran 
sulphate (DX)-induced acute colitis were used. The number of E.coli present in the urinary tract and 
the urinary and systemic inflammatory response (urinary leukocytes, urinary and systemic IL-6 levels) 
in mice with UTI were reduced by the LF treatment compared to the control group. Mice treated with 
LF peptide fragments (HLD1 and 2) also showed reduced numbers of bacteria in the kidneys. The 
perorally given LF was found to pass over to the circulation and urine. HLD2 mediated significant 
bactericidal activity against E.coli when tested in vitro in mouse urine. The damaging effects induced 
by DX exposure (presence of blood in the faeces, colon shortening, IL-lß serum levels, crypt score) 
were delayed or reduced in mice treated with LF or the peptides. The number of inflammatory cells 
present in the colon after 7 days of DX exposure (F4/80 macrophages, CD4- and TNF-a-positive 
cells) was lower in the LF treated group compared to the control. LF also reduced shortening of the 
colon when given orally to animals with an already established inflammatory response as induced by 
two days of DX exposure. LF was shown to down-regulate the secretion of TNF-a, IL-lß, IL-6, IL-8 
and IL-10 in monocytic cell lines (THP-1, Mono Mac 6) stimulated with LPS. The down regulation of 
the cytokines was reflected at the transcriptional level. Thus LPS-induced TNF-a-, IL-lß-, IL-6-, and 
IL-8 mRNA as shown by reversed transcription PCR were reduced as well. The known binding of LF 
to LPS could not explain the reduced cytokine mRNA expression and protein secretion since the 
effects were observed also when LF was added 30 min after the LPS to the cell assay. In addition, also 
IL-lß induced IL-6 secretion was down-regulated in the presence of LF. Moreover, LF was detected 
by immunocytochemistry in the cell nucleoli already after 30 min of incubation with the THP-1 cells 
and found by electromobility shift assay to decrease the binding of nuclear factor (NF)-kB to the TNF- 
a promoter. The antimicrobial activity against E.coli, S.aureus and C.albicans of synthetic peptides 
homologous to the surface exposed a-helix and ß-sheet region from the N-terminal end of human LF 
showed that a short region comprising 12-15 a.a. corresponding to the major part of the helix region 
were optimal for the killing activity against all three microorganisms. In addition certain amino acids 
such as cystein, and hydrophobic and positively charged amino acids in the 12-amino acid long 
peptide were found to be important for the expression of antimicrobial activity.
In summary, orally given LF can reduce infection and inflammation in a remote site such as the 
urinary tract, and mediates anti-inflammatory activities in the colon. This dual effect may partly reside 
in the antimicrobial region of the LF molecule, since synthetic fragments also provide similar 
activities. One possibly important mechanism of its anti-inflammatory effects is through the ability to 
down-regulate cytokine production via interference with the transcription factor NF-kB. The anti- 
infectious and anti-inflammatory activities of LF on mucosal surfaces is being utilized by the suckling 
child which obtains large amounts of LF via the maternal milk. However, therapeutic use of LF or its 
fragments may be possible in other fields of application.
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ABBREVIATIONS
a.a. amino acid
apoLF apolactoferrin
Arg arginine
bLF bovine lactoferrin
bLFcin bovine lactoferricin
BSA bovine serum albumin
CD cluster of differentiation
DX dextran-sulphate
hLF human lactoferrin
hLFcin human lactoferricin
holoLf iron saturated (holo) lactoferrin
HSA human serum albumin
IL interleukin
INF-y interferon gamma
LBP lipopolysaccharide binding protein
LF lactoferrin
LFcin lactoferricin
LPS lipopolysaccharide
mLF mouse lactoferrin
NF-kB nuclear transcription factor kappa B
PBS phosphate buffer saline
PBS-T phosphate buffer saline containing 0.05% Tween 20
PMN polymorphonuclear leucocytes
UTI urinary tract infection
TLR4 Toll like receptor 4
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INTRODUCTION
Lactoferrin
Lactoferrin (LF), a metal binding glycoprotein present in milk, mucosal secretions and 
secondary granules of neutrophils is an innate defense factor having antimicrobial and 
immunomodulatory activities. LF exerts broad-spectrum antimicrobial activity against 
bacteria, fungi and viruses (1,2). The regulation of immune responses by LF is a result of its 
ability to interact and affect the functions of the immune cells (3). Due to its high content in 
exocrine secretions and human milk, especially in colostrum, where it makes up 43% of the 
total protein, LF may constitute an important factor in the mucosal host defense and 
particularly in the infant.
Distribution ofLF
LF is present in the milk of all mammalian species (4). The levels in milk depend on the 
lactation period, being more elevated in colostrum than in transitional and mature milk (Table 
1) (5-7). In man the milk contains high concentration of LF, several order of magnitude 
higher than in cow's milk (4-6, 8). A human infant receives approximately 1-7 g of human 
lactoferrin (hLF) per day. The LF level in milk of other species varies (Table 1) (4).
External secretions of the respiratory, gastrointestinal and genitourinary tracts contain LF 
(Table 1). The levels of hLF are high in tears and genitourinary tract secretions, where they 
make up e.g. 20 and 10% of the total protein in the vaginal mucus and seminal plasma. 
Moderate levels are found in the respiratory and gastrointestinal tracts, and synovial fluid (1). 
The secondary granules of neutrophils also contain LF, which is released during inflammatory 
conditions (9). Cytokines (IL-lß, TNF-a) (10, 11), LPS, (12), and immune complexes (13) 
induce the release of LF from neutrophils. The plasma hLF level which is normally very low, 
can increase several orders of magnitude in infections and tumors reaching a concentration of 
e.g. 0.2 mg/ml in acute sepsis and 14 mg/ml in infected parotid fluid (12). It is likely that at 
sites of inflammations its concentration may reach milligrams per milliliter (14).
LF gene and synthesis
The hLF gene is located on chromosome 3q21 (15-17), the bLF gene on chromosome 22 (18), 
and the mouse LF gene on chromosome 9 (15). The LF gene is organized in 17 exons and the 
size varies depending on species between 23 and 35 kb (19-24). The gene encodes for 711 
and 708 a.a. in hLF and bLF, respectively. The first 19 a.a. residues of both proteins code for 
the signal peptide, the rest constituting the mature protein. The expression of the LF gene is 
cell-, tissue-, embryonic stage-, and hormone dependent as well as species-specific (25). 
Mutations and lower expression of the LF gene during oncogenesis compared with normal 
conditions has been observed (20, 26). A high mRNA expression of LF is found in normal 
human mammary gland, stomach and genitourinary tract (kidney, vagina, uterus, prostate, 
testis).
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Table 1. Distribution and levels of LF
Distribution mg/ml
Milk human colostrum 5-7
transitional 3.7
mature milk 1-3
rat, rabbit,dog <0.05
cow, goat, sow 0.001-0.1
mouse, guinea pig, 0.1-1
mare
Human tears 0.4-2.2
secretions
respiratory tract nasal secretion 0.1
saliva 0.005-0.01
bronchial mucus 0.03-0.04
gastrointestinal tract duodenal juice 0.00007-0.000172
pancreatic juice 
bile
0.000032-0.000072
small intestine u
genitourinary tract vaginal mucus 0.004-0.2 per 
mg protein
uterine secretions 0.5-1
seminal plasma 0.4-2
urine 0.001
amniotic fluid 0.002-0.032
Synovial fluid 0.01-0.08
Neutrophils 0.002-0.006 per
106 neutrophils
Blood 0.00009-0.0015
In contrast, no expression of LF is noted in the mouse kidney or stomach, while a higher 
expression is observed in the murine, than in human lung (25). In the endometrium and
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vagina the expression is up-regulated by estrogen (27), while in the mammary gland by 
prolactin (28).
LF is synthesized by epithelial cells of the mammary (29), lacrimary (30) and salivary glands 
(31), biliary tract (32), pancreas (31), uterus, cervix, vagina and prostate (27). LF present in 
neutrophils is synthetized during the transition of cells from promyelocyte to myelocyte (33). 
In mice, the protein was detected in the gestation in neutrophils of the fetal liver (embryonic 
day 11) and in the epithelium of the digestive and respiratory systems (embryonic day 16 
onward) (34).
Both hLF and bLF gene polymorphism exist (20, 35). hLF gene polymorphism has recently 
been reported within the exons 2, 5, 7, 9, 13, 14 and 15 of normal individuals (26, 36). The 
polymorphism in the exon 2, that affects the a.a. residues 11 (A or T) and 29 (K or R) of hLF 
is of importance with respect to the antimicrobial activity of the protein against S. aureus and 
Candida (36). Thus, the in vitro antibacterial activity of hLF from individuals homozygous 
for AK is ten times higher than of those homozygous for TR (36).
Isoforms of hLF, bLF and mLF are reported (37-41). Their existence is possibly a 
consequence of LF gene polymorphism and differential glycosylation of LF. Three hLF 
isoforms, hLF-ß and hLF-y with RNAse activity and iron binding property, and hLF-a with 
iron binding, but no RNAse activity have been isolated and characterized from milk and 
secondary granules of neutrophils (37, 38). Also, a delta hLF mRNA, a product of alternative 
splicing of the hLF gene, was detected in normal tissues having the highest expression in 
spleen, pancreas, colon, kidney and lung (42). The biological significance of the isoforms is 
presently unknown.
Structure of LF
LF belongs to the transferrin family of proteins having the structure closely related to 
transferrin. The a. a. sequence of different LF species was resolved by sequencing and cDNA 
cloning, while the three dimensional structure was resolved by X-ray crystallography (43-48). 
LF is constituted of a single polypeptide chain that comprises two homologous lobes, the N 
and C lobe. Each lobe contains one metal binding site and consists of two domains (N1 and 
N2, Cl and C2, respectively), which are linked by an a helix region. The domains form a 
cleft where 2 ferric ions (Fe+3) can bind synergistically with a bicarbonate anion (C032 ). The 
iron-saturated form is called hololactoferrin (holoLF), while the iron-depleted form is called 
apolactoferrin (apoLF). There is high homology in the a. a. sequence of LF from different 
species. Thus, hLF shows 69% homology with bLF and 70% with mouse LF, respectively 
(46, 49). hLF contains 691 a.a. according to one report (47), or 692 a.a. according to another 
one (43). It has a molecular weight of 78 kDa and two glycosylated sites (Asn 138 and Asn 
490) containing N-acetyl and poly N-acetyl lactosaminic type of glycans with structural 
microheterogeneity (50). The absence of ß 1-3 and 1-6 linked fucose residues and the 
homogeneity of the glycans in the neutrophil hLF constitute the difference with milk hLF. 
The N and C-globular lobes contain the amino acids 1-332 and 345-692 respectively. These 
are linked together by the a helix comprising the a.a. 333-344 (47). The protein moiety, 
especially the N terminal domain of the molecule mediates most of the biological activities of 
hLF (1). The two iron binding sites of hLF are similar. Iron binds to a.a. located in the
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positions Asp 60, Tyr 92, Tyr 192 and His 253 in the N lobe, and Tyr 435, Tyr 528, His 597 
and Asp 395 in the C lobe, and two oxygens from the anion C032'. It is estimated that only 6- 
8% of hLF in milk is iron saturated. The hLF is secreted into the exocrine fluids or released 
from the secondary granules of neutrophils as apoLF (51). The three dimensional structure of 
hLF is shown in Fig 1. bLF contains 689 amino acids (46) and 4 glycosylated sites with N 
acetyllactosaminic (Asn 368, Asn 476) and oligomannosidic type of glycans (Asn 233 and 
Asn 545 Asn 368, Asn 476). The iron binding sites of bLF are located in the same positions 
and identical a.a. as in the N lobe of hLF, and Asp 395, Tyr 433, Tyr 526 and His 595 in the C 
lobe (48, 52). bLF has an extra disulphide bridge (160-183), not present in hLF (53). Mouse 
LF consists of 688 a.a. and has only one N-acetyllactosaminic type of glycan (49, 54).
LF binds iron with a higher affinity than transferrin and retains it at lower pH (55). In the 
absence of iron, LF is able to bind other metals like copper, manganese, zinc, aluminium and 
gallium (56-60).
Fig. 1. The three dimensional structure of apo-hLF and holo-hLF. The ferric ions in 
holo-hLF are indicated by pink spheres. The glycosylation sites are only shown in 
holo-hLF. The region corresponding to the hLFcin fragment is highlighted in red.
LF metabolism
LF in milk is passing through the gastrointestinal tract of the suckling newborn. Little is 
known about the extent of LF degradation and the digestive segment responsible for it. LF 
and fragments were found in stools and urine of breast and formula fed human infants, 
suggesting the absorption of partially degraded protein in the gut (61-66). Receptors for LF 
are present in the small intestine of human infants (MW110 kDa) and adults (67), rhesus 
monkeys (68), mice (MW 130 kDa) (69, 70), rabbits (MW 100 kDa) (71), and piglets (72, 
73). While the human receptor is specific for hLF not binding bLF, the mouse receptor binds 
mLF, hLF, and bLF with similar affinities (70, 74). The biological role of the receptor is not 
elucidated, although there it is some evidence that is involved in the regulation of iron uptake 
in the gut (75). In vitro studies have shown that LF is relatively resistant to proteolysis by
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trypsin and chemotrypsin and the iron saturated LF is more resistant than the apo form (76). 
However, a pepsin derived fragment, called lactoferricin (LFcin) was generated from LF in 
vitro (77). bLFcin was found in the gastric content of an adult male as early as 10 min after 
oral feeding of bLF (78). The amount of LF surviving digestion in the gastrointestinal tract as 
intact protein was observed to decrease with age as observed in children (75). It still remains 
an open question to which extent the LFcin would be generated in the gastrointestinal tract of 
milk or LF-fed newborns, since the enzymatic digestive capacity of the infant is lower than in 
adults (low concentration of pepsin and other pancreatic enzymes, a higher gastric pH) (75). 
bLF and bLF fragments were also found in the gastrointestinal tract of animals fed bovine 
milk or milk supplemented with bLF. Thus, partly degraded bLF was detected in the stomach 
and small intestine of adult rats, and bLF fragments containing bLFcin were found in the 
faeces of adult mice fed milk enriched with bLF (79, 80).
LF released from neutrophils is transported to the liver where it is taken up by hepatocytes 
through asialoglycoprotein receptor mediated endocytosis and then released as degraded 
forms (81, 82). By binding with low affinity to chondroitin sulphate and specifically via 
residues 25-31 to the lipoprotein receptor related protein (LRP), LF can also be cleared from 
the circulation by the liver parenchymal cells (83, 84).
Antimicrobial effects of LF
Antibacterial effects of LF
Several studies have shown bacteriostatic and some bactericidal effects of LF against Gram 
negative and Gram-positive bacteria in vitro. The binding of LF to bacteria is suggested to be 
a prerequisite for its antibacterial effect (85). LF has shown to bind to E.coli, Prevotella 
intermedia, P. melaninogenica, and Porphyromonas gingivalis, and Streptococcus pyogenes 
(86-89). Specific receptors are reported for LF on S.aureus (MW 450 kDa), Neisseria and 
Moraxella species (MW 100 kDa), as well as Haemophilus influenzae (105 kDa) (87, 90-92). 
LF can exert its antibacterial effects by different mechanisms. One of the first described was 
withdrawal of iron, an essential bacterial nutrient, the antibacterial activity being restricted to 
the apoLF with holoLF inactive. However, some Gram negative bacteria can overcome the 
iron withholding effect of LF by synthesizing siderophores, which remove iron from LF (93). 
Also, some pathogenic bacteria e.g. Neisseria species utilize the iron from LF by expressing 
receptors for LF that can internalize the iron saturated form of the protein (91, 92, 94). These 
receptors are species specific, thus human pathogens can only use hLF as source of iron (95). 
LF acts synergistically with lysozyme and slgA against bacteria (96-99).
LF exerts the antibacterial activity by interacting with the bacterial cell envelope structures of 
both Gram-negative and Gram-positive bacteria. The cell wall of Gram negative bacteria is 
composed of an asymmetric outer membrane and a periplasm (100) (Fig. 2 A). The outer 
leaflet of the outer membrane is composed of lipopolysaccharide molecules (LPS) 
(approximately 3.5X106 per cell in E.coli), lipoproteins and proteins and the inner leaflet of 
mainly phospholipids. LPS is an amphiphilic molecule composed of the O-specific chain 
consisting of repeating oligosaccharide units; the core region containing the sugar 2-keto-3 
deoxyoctulonic acid, heptose, and free phosphate groups; and lipid A, a glycolipid inserted 
into the membrane, composed of a biphosphorylated ß (1-6) linked D-glucosamine
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disaccharide and up to seven long chain fatty acids. There are, however, structural variations 
in the lipid A part. Divalent cations (Ca2+ and Mg2*) are also integrated in the outer leaflet of 
the membrane in order to stabilize the anionic character of the core oligosaccharide. The outer 
membrane contains the outer membrane proteins (OMPs), including porins (e.g. OmpC, 
OmpF and PhoE of E.coli), which form pores accounting for the permeability to hydrophilic 
molecules (101, 102). The periplasm is constituted of a thin, rigid layer of peptidoglycan (or 
murein), a lipoprotein attaching the peptidoglycan to the outer membrane, and a variety of 
hydrolytic enzymes. Essential for maintenance of the three dimensional shape of bacteria, the 
peptidoglycan is made up of a polysaccharide (polymer of N-acetyl-glucosamine and N- 
acetyl-muramic acid) cross-linked by peptides. The inner membrane has a phospholipid 
bilayer structure, which unlike eukaryotic membranes, does not contain cholesterol. The inner 
membrane contains integrated membrane transport proteins, ion pumps and enzymes.
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Fig. 2. Schematic representation of the cell envelope in Gram-negative (A) and Gram-positive 
bacteria (B). OM, outer membrane; PS, periplasmic space; CW, cell wall; CM, cytoplasmic 
membrane.
In Gram negative bacteria, both hLF and bLF bind to and release LPS, destabilizing the outer 
membrane and increasing the bacterial killing by lysozyme (103, 104). Several studies have 
shown that LF binds to LPS and to the lipid A moiety, and the a.a. residues 1-5 and 28-34 of 
hLF are involved in this binding (105-109). LF binds via a.a. residues 1-5, 28-34, and 39-42 
to the E.coli porins ( e.g. OmpF, OmpC and PhoE), thus affecting the bacterial outer 
membrane permeability (110, 111). It is believed that LF destabilizes the outer membrane of 
Gram negative bacteria without penetrating it (103, 112).
Unlike Gram negative bacteria, Gram positive bacteria do not have an outer membrane as a 
part of their cells wall and being multilayered, their peptidoglycan is much thicker (113) (Fig 
2 B). As a part of the Gram positive cell wall, the teichoic and lipoteichoic acid 
polysaccharides are linked by phosphodiester bridges to the N-acetyl muramic acid of the
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peptidoglycan and covalently linked to the glycolipid of the cytoplasmic membrane, 
respectively (Fig. 2B).
In Gram positive bacteria hLF interacts with lipoteichoic and teichoic acid (114). The 
binding, neutralization of negative charges, and release of lipoteichoic acid from 
Staphyloccocus epidermidis by hLF, with a subsequent increase in the susceptibility to 
lysozyme was shown (114). hLF seems to induce intracellular changes in bacteria (e.g. 
affecting nonspecific esterase activity) without affecting the cytoplasmic membrane 
permeability (115). The first two arginine residues in position 2-3 (Arg:-Arg3) are important 
in the killing activity of hLF against S. aureus bacteria (115).
A third mechanism of antimicrobial activity of LF is the release of the microbicidal LFcin 
fragments upon enzymatic hydrolyzis (116). They are more potent in killing Gram negative 
and Gram positive bacteria than the native proteins. The structure of LFcin is shown in Figs. 1 
and 3.
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Fig 3. Amino acid structure of hLFcin and bLFcin. Single letter code is used to indicate the amino 
acid sequence. Basic amino acids are indicated in bold.
On a molar basis, hLFcin and bLFcin is 2-and 12-fold more active than the parent molecules 
and bLFcin 9-fold more effective than hLFcin against E. coli Olll (77). hLFcin corresponds 
to the a.a. residues 1-47 of the N1 terminal domain of hLF. This fragment contains the 
antibacterial (a.a. residues 18-40) and the LPS binding domains (residues 1-5 and 28-34) (77, 
107). bLFcin corresponds to a.a. residues 17-41 with a disulphide bond between a.a. 19 and 
36. The a.a. residues 17-28 adopt an a helix, 29-31 a turn, and 31-41 aß sheet in the native 
protein (77). However, by NMR, bLFcin has been shown to adopt a distorted antiparallel ß- 
sheet (117). In aqueous solutions the peptides adopt random conformations. The loop region 
of hLFcin (a.a. 20-37) resides in an exposed surface of the N1 domain of hLF and adopts an a 
helix (a.a. 21-31) with the hydrophobic tail (a.a. 32-36) in the native protein (118). The 
synthetic peptide corresponding to a.a. 21-31 of hLFcin was found more active than the entire 
loop region, while the peptide corresponding to the hydrophobic tail was found inactive 
against several bacteria (118). The peptide 21-31 showed an increased bacteriostatic effect 
against Staphylococcus aureus compared to E.coli (118). The a.a. residues 1-17 of hLFcin 
were initially shown not to be important in the antibacterial activity. However, a recent study 
has shown that the synthetic peptide containing the first cationic domain of hLFcin (a.a. 1-11) 
is even more active than the peptide containing the second cationic domain (21-31) (77, 115). 
The peptide 1-11 has even found more potent in vivo than in vitro, when given intravenously
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to mice 24 hrs after an experimental S. aureus or K. pneumoniae infection induced in muscle 
(115).
The bactericidal mechanism of LFcin and synthetic peptides is not well defined. The synthetic 
peptide corresponding to a.a. residues 21-31 of hLFcin binds to LPS, enters to and disrupts 
the outer membrane of E.coli 0111 (118). The synthetic peptide corresponding to residues 
18-40 of hLFcin interacts with the inner membrane of E.coli 0111 (119). The peptide 1-11 is 
suggested to affect the membrane permeability of S. aureus (115).
As the native protein, bLFcin destabilizes the outer membrane of Gram negative bacteria and 
releases even more LPS from the membrane than bLF (112). In Gram positive bacteria 
bLFcin binds to teichoic acids (120). bLFcin also acts on and affects the permeability of the 
cytoplasmic membranes of Gram positive and Gram negative bacteria (116, 121). bLFcin has 
recently been shown to cross the cytoplasmic membrane and reach the cytoplasm of E.coli 
and S. aureus (122).
Through its oligomannosidic type of glycans, bLF inhibits the adherence of type 1 fimbriated 
E.coli, and Helicobacter bacteria to the host cells (123, 124).
The antibacterial role of LF, especially of hLF or peptides is less studied in vivo. LF protects 
mice against systemic experimental E.coli and 5. aureus infections (125, 126). Thus, bLF 
given intravenously 24 hrs before the systemic E.coli challenge reduced the lethality of the 
animals and the number of bacteria in the kidneys and lung (125). hLF given intravenously 
(i.v) and bLF given i.v. or orally one day before intravenous inoculation with S. aureus 
significantly reduced the number of bacteria present in kidneys after 14 days of infection 
(126). Daily oral administration of bLF for 4 weeks starting three weeks after oral inoculation 
with Helicobacter pylori decreased the number of bacteria in the stomach of Balb/c mice 
(124). The effect was attributed to the inhibitory activity of bLF on the adherence of bacteria 
to the gastric epithelium (124). In an experimental model of colonization with Clostridium, a 
decreased number of bacteria was found to translocate to the mesenteric lymph nodes and to 
be present in the feaces of mice fed milk supplemented with bLF or pepsin-derived bLF 
hydolysate, indicating bacteriostatic effect of bLF in the gut (123, 127).
A protective effect of orally given LF against enteric infections in neutropenic human 
individuals was reported (128).
Antifungal effects ofLF
Fungistatic and fungicidal effects mostly against Candida albicans have been described for 
hLF, bLF, bLFcin, a peptide based on bLFcin (a.a. 17-26), and a peptide based on hLFcin (a.a. 
1-11) (129-133). The apoLF is more effective than holoLF, and the LFcins more than the 
native proteins with respect to the antifungal activity (129, 130,133).
The outer cell wall layer of Candida albicans is composed by a phosphomannoprotein 
complex constituted by mannan (polymers of mannose) covalently linked to proteins and 
containing 1-2% phosphate. The structural components of the cell wall are ß-glucans 
(branched polymers of ß 1-3 and ßl-6 glucose) as main constituents and chitin (unbranched 
polymer of ßl-4 bound N-acetyl-D glucosamine) as minor constituent. In addition, the cell 
wall contains proteins and lipids (134). Unlike bacteria, the cytoplasmic membrane of fungi
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contains ergosterol. The schematic composition of C. albicans cell wall and cytoplasmic 
membrane is shown in Fig. 4.
Fig. 4. Schematic representation of C. albicans cell wall and cytoplasmic membrane. CM, cytoplasmic 
membrane.
hLF interacts with the mannoproteins from the cell wall of Candida albicans (135) and 
induces fungal cell surface alterations, formation of surface blebs and leakage of proteins
(130) . A hLF peptide corresponding to the first 11 a.a. of hLF (1-11) was recently found more 
effective in killing C. albicans than a peptide corresponding to a.a. 21-31 of hLF (133). The a. 
a. residues Arg2-Arg3 of the peptide 1-11 and the peptide-induced extracellular release of 
fungal ATP are important in the killing activity (133). The optimal binding of bLFcin to 
Candida albicans at pH 6 and in the absence of Ca2+ and Mg2+ correlates to its killing capacity
(131) . Synergistic effects of hLF, bLF and bLFcin with antifungal drugs e.g. clotrimazole and 
fluconazole has been reported (136, 137).
Immunomodulatory and anti-inflammatory effects of LF
Inflammation
Inflammation is a complex process by which a tissue responds to a damage or an infection. 
An increase in the blood supply and capillary permeability, and the migration of leukocytes 
and serum proteins to the area occurs initially. In general, the neutrophils are the first cells 
arriving at the site of an acute inflammation followed by monocytes and activated 
lymphocytes. CD8+T cells and B cells usually arrive later. The chemokines, such as IL-8 
synthetised by the cells present in the tissue or by endothelial cells trigger the migration of 
neutrophils to the inflammatory site. Mononuclear phagocytes release proinflammatory 
cytokines such as TNF-a, IL-lß and IL-6. IL-lß and TNF-a induce the expression of E 
selectin, and ICAM-1 and VCAM-1 adhesion molecules on the endothelium. ICAM-1 and 
VCAM-1 molecules bind to LFA-1 (aLß2), VLA-4 (a4ßl) and CR3 (a M ß2) integrins on
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leukocytes, resulting in the cell migration through the endothelium to the tissue. IL-lß and 
TNF-a also induce the production of IL-8 by macrophages and endothelial cells. The cells 
arrived at the site of inflammation release mediators that activate and recruit other cells. 
Activated macrophages produce MIP-la and leukotriene LTB4 which being chemotactic, 
attract more monocytes to the tissue. The lymphocytes release INF-y and TNF-ß which 
activate macrophages and enhance their phagocytic activity.
The complement, the clotting, the fibrinolytic, and the kinin systems are serum plasma 
molecules involved in the inflammatory response. Auxiliary cells like platelets, mast cells and 
basophils are sources of mediators such as histamine and serotonin, which are important in 
vasodilation and vascular permeability. An acute local inflammation is accompanied by a 
systemic response, IL-lß, TNF-a, IL-6 inducing the production of the acute phase proteins by 
the liver. If the stimuli or the infection is not cleared, an acute inflammatory response can 
develop into a chronic one (138).
LPS as a potent inducer of cytokines in monocytes
Monocytes/macrophages are important cells of the innate immune system that respond to 
bacteria and bacterial components by secreting cytokines, mediators like NO, and reactive 
oxygen species. LPS, the main component of the outer membrane of the Gram-negative 
bacteria stimulates monocytes/macrophages to produce cytokines like IL-1, TNF-a, IL-6, IL- 
10 and chemokines like IL-8. LPS binds to LBP present in serum at 3-10 (ig/ml, which then, 
catalyze the transfer of LPS to the CD14 receptor (139). CD14 receptor does not posses a 
transmembrane domain, being expressed on the surface of the myeloid cells via a 
glycosylphosphatidylinositol tail (membrane CD 14) which anchor the protein in the 
membrane (140). CD14 is also present free in plasma (2-6 pg/ml) as soluble CD14 (sCD14) 
and mediates LPS activation (141). LPS then interacts with the signaling receptor Toll like 
receptor 4 (TLR4) and the accessory protein MD-2 (142). As a result of this interaction the 
NF-kB and three MAPK kinases (p38, JNK, ERK1/2) signal pathways are activated (142). 
NF-kB is a transcription factor involved in the transcription of many proinflammatory 
cytokine genes (IL-lß, TNF-a, IL-6, IL-8, IL-12). NF-kB exist in the cell cytoplasm in an 
active form consisting of the heterodimers p50/p65 associated with the inhibitory unit IkB 
(143). Upon LPS stimulation, the phosphorylation of IkB occurs, NF-kB nuclear localization 
signal is revealed, the transcription factor translocates to the nucleus, binds to and activates 
transcription of the target cytokine genes (144).
The effect of LF on immune cells
LF contributes to the host defense mechanisms not only through its anti-microbial effects, but 
also by modulating the immune system via its ability to bind to and affect the functions of 
immunocompetent cells. LF has effects on the majority of the cells of the immune system 
(monocytes/macrophages, Langerhans, neutrophils, y8 T cells, NK cells, platelets, B and T 
cells) (1, 145-147). The underlying mechanism of most of its activities is unknown. Some of 
the effects are dependent, while others independent on the iron saturation status of LF (1). 
Being a cationic protein, LF binds to the cells in two ways. The charge-charge interaction of 
LF with proteoglycans, or membrane DNA accounts for a low affinity binding of the protein
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to the cells. A higher affinity, but lower capacity of binding to the membrane receptor(s) 
constitutes the second way of interaction of LF with cells.
LF effects on monocytes
Due to its high concentration at mucosal surfaces and release from neutrophils at sites of 
inflammation, it is very likely that LF interacts with mononuclear phagocytic cells in vivo. 
Low and high affinity binding sites for LF are present on human blood monocytes (148-150), 
monocytic cell lines e.g. THP-1 (151-153), U937 (154), monocyte/macrophage differentiated 
HL-60 (105), as well as human alveolar (155) and mouse peritoneal macrophages (156). The 
binding is independent on the iron content of LF (151, 157). In all studies milk, not neutrophil 
derived LF is used. This could be of relevance for interpretation of binding to macrophages of 
hLF released from neutrophils, since the fucose residue present on milk, but not on neutrophil 
hLF could be involved in binding to mannose receptors present on macrophages. The binding 
of LF to the monocyte proteoglycans, present in a higher amount on these cells than on other 
cell types, could explain the ionic and low affinity interaction of LF with monocytes. An ionic 
interaction in binding of hLF to alveolar macrophages is described (155). The basic cluster of 
four arginine residues in position 2-5 (Arg2-Arg5) and the a.a. residues 28-31 of hLF is 
involved in the binding to glycosaminoglycans (158). Several hLF-binding proteins on THP-1 
cells (MW of 35, 50 and 80 kDa) exist (152). hLF and bLF bind with similar affinity to THP- 
1 cells. The binding is mediated mainly by the protein moiety of hLF, and to a minor extent 
via its polylactosaminoglycans (152, 153). The cytokine secretion and the phagocytic capacity 
of monocytes/macrophages are affected by LF in experiments in vitro. Iron saturated LF has 
been proposed to inhibit myelopoiesis through down regulation of GM-CSF via inhibition of 
monocytic IL-lß (159-162). LPS-induced IL-lß, TNF-a, and IL-6 in human and murine 
monocytes and monocytic cell lines are down regulated by LF. IL-6 is also inhibited by 
bLFcin as shown in vitro (145, 163, 164). Binding of LF to LPS and soluble CD14, as well as 
competition with LBP for binding to LPS could partly explain the inhibitory activity of LF on 
cytokine secretion (105, 109, 165). LF also inhibits the PMA-induced prostaglandin E2 
production of human breast milk macrophages (166). Although the internalization of hLF in 
monocytes/macrophages is shown by several studies (150, 167-170), the fate of the protein 
intracellularly is not fully elucidated. Studies using subcellular fractionation techniques 
showed the internalization of iron saturated hLF into a myeloperoxidase-positive lysosomal 
fraction (170), and of apoLF in the cytosolic fraction (150). By immunoelectron microscopy 
iron saturated hLF was detected in the endoplasmic reticulum and in the nucleus (169). After 
binding and uptake of iron saturated hLF into monocytes, 50% of its iron is transferred to the 
cytosolic ferritin. Thus hLF was proposed to participate to the hyposideraemia of infections 
(167, 170, 171). However, this debated effect (154) seems less likely to occur in vivo, since 
the ability of LF to remove iron from plasma transferrin and deliver it to the macrophage 
ferritin is extremely slow (172). Moreover, the IL-lß-induced hyposideraemia can be seen in 
neutropenic mice, indicating that neutrophil derived LF does not contribute to this condition 
(173).
Increased uptake and killing of intracellular Trypanosoma cruzi and Listeria monocytogenes 
parasites by murine macrophages and human monocytes in the presence of hLF were
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reported. The intracellular killing, but not the uptake of the microorganism was dependent on 
the iron saturation of hLF (174, 175). Iron delivery by LF to an oxygen radical generating 
system in an acidic environment such as a phagolysosome seems to be responsible for the 
mechanism of killing (1, 175). However, at normal extracellular pH, apoLF acts rather as an 
iron scavenger and inhibits the radical production, thus protecting the cells from oxidative 
damage (1,150).
LF effects on neutrophils
Neutrophils are the first cells recruited to the site of infection and inflammation. LF affects in 
vitro important functions of these cells like mobility, hydrogen production and killing of some 
microbes. Thus, LF possibly affects the migration of the cells to the inflammatory sites in 
vivo. As for monocytes/macrophages, low and high affinity binding sites of milk hLF on 
human blood neutrophils are reported (176, 177). However, the binding of hLF to neutrophils 
is approximately ten times lower than to macrophages or lymphocytes (177). By binding to 
neutrophils, hLF can reduce the charge of the cells and promotes their adherence to the tissue 
(178). hLF increases the mobility and superoxide production induced by stimuli such as 
zymosan, PMA and FMLP in human neutrophils, althought the killing of S.aureus is not 
affected (179). While the mobility of the cells is increased regardless of the iron saturation of 
LF, the generation of superoxide by iron saturated LF is higher than for native LF (179). The 
phagocytic activity of human blood neutrophils is stimulated by bLF and bLFcin as 
determined by incorporation of latex beads (180). An augmentation of neutrophil killing 
capacity of Candida albicans in the presence of bLF, bLfcin and a bLFcin-derived peptide 
was also shown (132, 181). By its ability to bind to LPS, hLF prevents the binding of LPS to 
L-selectin and the production of reactive oxygen species from neutrophils (165). hLF protects 
the neutrophils from oxidative damage by inhibition of lipid peroxidation (182) possibly by 
its ability to bind iron and inhibit hydroxyl radical production at physiologic pH (1).
LF effects on T cells
LF affects the proliferation, differentiation and cytokine production of T cells. LF was shown 
both to inhibit (183, 184) and stimulate the proliferation of T cells (185-188). This dual effect 
seems to be modulated by the environmental conditions, LF affecting the T cell proliferation 
by regulating the iron uptake, the effects being inhibitory at low iron levels and stimulatory in 
excess of iron (189, 190). LF has also been shown to induce the differentiation and maturation 
ofT cells (191, 192).
The effects of LF in T cells are possibly mediated via the receptor described on the cells. The 
only hLF receptor described on T cells is a glycoprotein with MW of 105 kDa (186, 193). The 
receptor recognizes the residues 4-52 in the N1 terminal domain of the hLF, which forms two 
exposed loops with a ßaßa structure (147).
LF effects on B cells
LF affects the proliferation and differentiation of B cells. Both hLF and bLF have shown to 
increase proliferation of human, but not mouse cell lines in serum free medium (185). Iron 
saturated hLF induces the maturation of spleen B cells isolated from 7-8 days newborn mice 
as detected by increased expression of IgD and complement receptors (C3R) maturation
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markers on these cells (194). Iron saturated hLF also enables the spleenic B cells from normal 
Balb/c newborn and adult CBA/N deficient mice (lacking B cell function as antigen 
presenting cell) to acquire in vitro the antigen presenting cell function (194). LF and bLFcin 
have recently shown to bind to CpG bacterial oligonuleotide and to inhibit the binding and 
internalization of these immunostimulatory molecules in B cells (195).
The a.a. Arg2-Arg3 residues at the N terminal domain of hLF are important in the interaction 
ofLF with B cells (196).
LF effects on NK cells
The augmentation by LF of NK cells cytotoxicity (146, 197, 198), inhibition of the tumor 
growth (199), and of angiogenesis (200), may partly explain the reported antitumoral 
activities of LF on colon, urinary bladder, esophagus and lung carcinoma in animal models 
(201-205).
LF effects on platelets
The inhibition of platelet aggregation and thus an anti-coagulant effect of LF was reported by 
in vitro studies (147). This inhibition could be due to the structural analogy between the 
sequence target of the platelets GpIIb-IIIa complex (RGDS), and the residues 39-42 (KRDS) 
of hLF (206). The LF receptor on the surface of platelets is similar to the lymphocytic 
receptor (147).
Anti-inflammatory effects ofLF in vivo
There are few reports studying the anti-inflammatory effects of LF in vivo. The most explored 
in vivo model is endotoxemia. Thus, intravenous administration of bLF to mice not earlier 
than 24 hrs before the challenge with LPS decreased the TNF-a levels in serum (207). 
Protection against lethal endotoxic shock in germfree, colostrum-deprived piglets using 
repeated oral administration of bLF before intravenous LPS challenge was reported (208). 
The ability of bLF to block the LPS in vivo was suggested to be a consequence of inhibition 
by bLF of LPS binding to piglet monocytes, as shown by in vitro studies (208). hLF 
administered intraperitoneally 1 h before LPS challenge reduced the mortality in mice and 
protected the small intestine from the damages induced by LPS (209). Topical application of 
hLF on skin inhibited allergen-induced cutaneous inflammation in mice and human 
volunteers (210-212). Thus, oxazolone- and diphenylcyclopropenone-induced Langerhans 
cell migration from epidermis and dendritic cell accumulation in the draining lymph nodes 
were inhibited by topical application of hLF via down-regulation of TNF-a produced by 
kératinocytes (210-212).
LF and transcription
Using the K565 cells and human blood monocytes hLF was shown to be taken up and 
transported to the nucleus (169, 213). Recently, a peptide corresponding to the a.a. 1-5 of hLF 
was found to be localized to the nucleoli of various cell lines such as cervix epithelial, 
(HeLa), glioblastoma (U87MG) and bladder carcinoma (5637) cell lines (214). This peptide 
was proposed to be the nuclear localization signal of hLF (214).
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hLF binds to three specific DNA consensus sequences and regulates the transcription of the 
reporter genes containing these sequences in the promoter region (215).
Urinary tract infection (UTI) mouse model
The urinary tract is normally sterile. Several factors such as urine flow, bactericidal and anti­
adherence molecules present in the urine (like lysozyme, LF, defensins, IgA, uromodulin, low 
molecular oligosaccharides) contribute to maintain this sterility (216). However, 
uropathogens have developed strategies to overcome the defense mechanisms, by adhering 
and colonizing the urinary tract epithelium. They induce a local inflammatory response in 
susceptible individuals. The large intestine, vaginal introitous, and periurethral area are the 
sources of the E. coli, which is the most common uropathogen (217). After the ascendance up 
into the urinary tract, bacteria may cause different manifestations of UTI that vary in 
pathogenesis and severity, such as asymptomatic bacteriuria, acute cystitis or acute 
pyelonephritis (217).
The interplay between the bacterial virulence factors and the host response to infection 
reflected by the severity of the UTI was studied in detail using a mouse model (218-221). The 
adherence of bacteria via fimbriae to the urinary tract epithelium constitutes the first step in 
the pathogenesis of UTI (222, 223). The uroepithelial cell receptors for type P fimbriae 
consist of glycoshingolipids of the globoseries (Galal-4ßGal containing oligosaccharides 
bound to ceramide in the cytoplasmic membrane), while type 1 fimbriae binds to 
mannosylated glycoproteins (224, 225). Using TLR-4 proficient (C3H/HeN) and defective 
(C3H/HeJ) mice and different mutated bacterial strains, LPS, bacterial fimbriae, especially 
type P, but also type 1, have shown to be important for inducing a local mucosal 
inflammatory response characterized by the secretion of the pro-inflammatory cytokines IL-6 
and IL-8, and the subsequent recruitment of PMNs into the urine (220, 223, 226, 227). Type P 
and 1 fimbriated bacteria utilize different signaling pathways for activating the uroepithelial 
cells, that have recently been elucidated (219, 220, 227). P fimbriated bacteria induce a 
cytokine response in epithelial cells by utilizing the ceramide signal pathway, and TLR4 as 
coreceptor (219, 227), while type 1 fimbriated bacteria trigger one LPS and TLR-4 dependent, 
and one lectin-dependent but TLR-4 independent signaling pathway (220). The innate 
immunity provided the most efficient defense mechanism against UTI, since by depleting the 
neutrophils the host resistance to infection decreased (228). Thus, C3H/HeJ mice responded 
to bacterial infection with much lower number of influxing neutrophils and IL-6 levels in the 
urine and, unlike the normal mice, that normally clear the infection within 3-7 days, they 
remained infected (229). IL-8 and IL8 receptor are involved in the recruitment and migration 
of neutrophils across the infected urinary tract mucosa as illustrated in studies with IL-8 
receptor knockout mice (221, 230).
The adaptive immunity does not play a major role in the early defense against UTI infection, 
since no difference with respect to resistance to infection was seen in lymphocyte deficient 
mice (nude, xid, seid, ßTCR mutant, yTCR mutant, RAG-1 mutant) and their 
immunocompetent counterparts (231).
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Dextran-sulphate (DX)-induced colitis mouse model
Unlike the urinary tract, the gut mucosa is constantly exposed to bacteria of the commensal 
flora. The bacterial species and number differ along the intestinal tract, with the highest 
population harboured in the colon (10"-1012 bateria/g faeces in man) (232). The defense 
mechanisms at the mucosa of the gut face the difficult task to mount harmless responses to 
indigenous flora, while promptly counteracting the harmful antigens and pathogens. 
Unbalanced immune responses in the gut lead to inflammatory bowel diseases (IBD). IBD 
comprises two main clinical manifestations of gut inflammation, ulcerative colitis (UC) and 
Crohn's disease. UC affects predominantly the large intestine and in Crohn's disease any part 
of the gastrointestinal tract may be involved (233).
An experimental model, resembling features of human ulcerative colitis, induced by giving 
DX in the drinking water was described in mice, rat and hamsters (234-236). Giving DX to 
the animals over 7 days induces an acute colitis (234). DX is a sulphated polysaccharide, the 
polymer part consisting of repeating units of ß 1-6 glucose, and it is synthesized commercially 
from dextran produced by the lactobacillus Leuconostoc mesenteroides (237). A molecular 
weight of 30-40 kDa and a sulphur content of 15-17% were found to be optimal 
characteristics of DX for inducing colitis in mice (238). The histopathological changes 
induced by DX consist in epithelial exfoliation and recruitment of the inflammatory cells 
(macrophages, neutrophils, lymphocytes), with the involvement of the colonic mucosa, and in 
the later stages of the submucosa, where the oedema could be observed (239). The course of 
colitis was reported to be more severe in the endotoxin responsive mice at the later stage 
(240). The exact mechanism by which DX induces colitis is not completely elucidated. Direct 
cytotoxicity of DX on the intestinal epithelial cells, macrophage derived cytokines, and a 
macrophage impaired phagocytosis of bacteria were proposed to contribute to the 
pathogenesis of the model (239,241, 242). Thus, macrophages were suggested to be crucial in 
the model. Macrophages containing DX were detected in the colonic mucosa, liver and 
mesenteric lymph nodes of animals, as early as after 1 day of DX exposure (243). An 
increased number of macrophages were detected by immunohistochemistry in the colonic 
mucosa, especially after seven days of DX exposure (244, 245). Elevated levels of 
macrophage derived cytokine mRNA and protein were reported in the colon (IL-la, IL-lß, 
IL-6, TNF-a, IL-12), and draining lymph nodes (IL-lß, IL-6, TNF-a) of the animals exposed 
to DX (244, 246-248). The macrophage-induced cytokines may contribute to the tissue injury. 
IL-lß was shown to be important in the development of colitis, since the neutralization of this 
cytokine with antibodies improved the damages induced by DX (246). The T, B, NK and mast 
cells does not play a significant role in this model, since the colitis can be induced in SCID 
and T, B, NK and mast cell depleted mice (248-250).
The role of bacteria in the acute DX induced colitis is controversial, some studies showing the 
development of colitis in germ free animals, while an amelioration of the damages induced by 
DX is seen in studies using antibiotics (251-253). However, a shift in the normal colonic flora 
with increased numbers of Clostridium spp., Bacteroidaceae and Enterobacteriaceae is 
observed (234).
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AIMS OF STUDIES
The major aim of the thesis was to investigate the anti-infectious and anti-inflammatory 
activities of LF and fragments thereof in vivo. In particular, studies were focused on:
• The anti-infectious effects of orally administered LF and two LF peptides, based on 
the anti-bacterial region of hLF molecule, on E.coli induced UTI in mice (I).
• The anti-inflammatory effects of orally given hLF on dextran-sulphate (DX)-induced 
acute colitis in mice (II).
• The mechanism for the inhibitory activity of LF on LPS-induced cytokine production 
in monocytic cell lines (III).
• Structural requirements for the microbicidal activities of the surface exposed helix- 
loop region of hLF (IV).
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MATERIAL AND METHODS
LF and peptides
hLF and bLF from human milk and bovine colostrum respectively, were purchased from 
Sigma Aldrich (Stockholm, Sweden). The iron saturation of the LF batches used in the thesis 
was approximately 7%. The purity of LF was checked by SDS-PAGE electrophoresis.
The presence of the basic cluster of 4 arginine residues from the N-terminal domain of hLF 
corresponding to amino acids 2 to 5 (Arg2-Arg5) was checked by chromatography on Mono S 
column (254). The synthetic peptides used in the thesis were based on the antibacterial region 
of the hLF comprising an a helix and a ß sheet (Fig. 5) and are shown in Tables 2 and 3 (I, 
IV). The hLF peptides were synthesized by a 9-fluorenyl-methoxy carbonyl continuos-flow 
strategy on a Biosearch Pioneer automated peptide synthethizer. Some peptides were capped 
at the N-(Ac) and C-(NH2) terminal ends in order to neutralize the otherwise charged ends, 
which would not be present in the hLF molecule. HLD1 (referred to as HLBD1 in study IV) 
was made either linear or cyclic by introducing a disulphide bridge between the cystein 
residues. In HLD2 (referred to as HLBD2 in study IV) the cystein residues (C) were changed 
to acetamidomethylcystein (Cm) in order to avoid spontanous disulphide bridging. The 
peptides based on the helix region of hLF and the modifications made in the natural sequence 
are shown in Table 3.
a.a.residue
a-helix ß-sheet
14 20 25 30 35 40
QPEATKC FQWQRNMRKVRGPPVS C IKR 
I I
Fig. 5. Natural sequence of the antibacterial aß helix region of hLF
Table 2. Peptides based on the antibacterial aß region of hLF. The disulphide bridges 
between the cystein residues are indicated by lines.
Peptide code (MW) sequence
HLD1 (3057 g/mol) 
or HLBD1
Ac - E A T K p FQWQRNMRKVRGPPVS Cj IKR-NH2
HLBDl(Acm) (3201 g/mol) Ac - E A T K CmF QWQRNMRKVRGPPVS Cm IKR- NH2
HLD2 (3002 g/mol) Ac - T K CmF QWQRNMRKVRGPPVS Cm I K R - NH2
or
HLBD2
HLBD3 (3430 g/mol) KC FQWQRNMRKVRGPPVS C I
1 1
HLBD3(Acm) (3576 g/mol) KCmF QWQRNMRKVRGPPVS CmI
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Table 3. Peptides based on the antibacterial a-helix region ofhLF. The modifications made 
in the natural sequence are highlighted in bold. The lactam and disulphide bridges are
indicated with lines.
Peptide code sequence
Downsizing the helix region:
HLBD4 QPEATKC FQWQRNMRKVR
HLBD5 PEATKC FQWQRNMRKVR
HLBD6 EATKC FQWQRNMRKVR
HLBD7 ATKC FQWQRNMRKVR
HLBD8 TKC FQWQRNMRKVR
HLBD9 KC FQWQRNMRKVR
HLBD10 C FQWQRNMRKVR
HLBD11 FQWQRNMRKVR
HLBD 12 QWQRNMRKVR
Alanine scan:
HLBDalal A FQWQRNMRKVR
HLBDala2 C AQWQRNMRKVR
HLBDala3 C FAWQRNMRKVR
HLBDala4 C FQA QRNMRKVR
HLBDala5 C FQWARNMRKVR
HLBDala6 C FQWQANMRKVR
HLBDala7 C FQWQRAMRKVR
HLBDala8 C FQWQRNAR KVR
HLBDala9 C FQWQRNMAKVR
HLBDalalO C FQWQRNMRAVR
HLBDalal 1 C FQWQRNMRKAR
HLBDalal 2 C FQWQRNMRKVA
Substitution of the same kind of a.a. 
HLBDskl3 C FQ LQ RNMRKVR
HLBDskl4 C FQWQ KNMRKVR
HLBDskl5 CFQWQRNLRKVR
HLBDsklô C FQWQ RNMKKVR
Negatively charged a.a.:
HLBDE17 C FQWE RNMR KVR
HLBDE18 C FQWQ ENMR KVR
HLBDE19 C FQWQ REMR KVR
Charged or hydrophobic a.a.: 
HLBDsub20 CFQW Or RNMRKVR
HLBDsub21 C FQW N1 RNMRKVR
HLBDsub22 C FQWQROrMRKVR
HLBDsub23 C FQWQ RN1MRKVR
Substitution:
HLBD 1 Oopt 1 C FQW KRNMRKVR
HLBD10opt2 C FQW KRAMRKVR
HLBD10opt3 C FA W KRNMRKVR
HLBDI0opt4 C FAW QRAMRKVR
HLBD10opt5 C FQL QKNMKKVR
HLBDIOoptô C FAL KKAMKKVR
Lactam bridges:
I-------- 1
HLBD!( 18-22)2 (3069 g/mol) Ac-EA£KC F K W Q RN M R K V R G P P V S C I fC R - Amid
I---------- 1
HLBDl(18-22)2 (3056 g/mol) Ac-EATKC YE WQRÏMRKVRGPP VS C IKR-Amid
HLBD 1(18-22)2 (3085 g/mol)
Ac-EATKC FQ WQR£*M RKff RGPPVS C IKR-Amid
J
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The modifications of the natural sequence of antibacterial a helix region of hLF were 
obtained by replacing certain a.a.s with alanine (A), leucine (L), lysine (K), glutamic acid (E), 
ornithine (Or) and norleucine (Nl). In some peptides the lactam bridges were introduced at 
different positions between a.a.s E and K in order to induce some helix formation (Table 4). 
HLD1 cyclic and HLD2 linear peptides were used in the in vivo experiments (I, II), while 
both HLD1 cyclic and linear, HLD2, as well as the other peptides were used in in vitro studies 
(IV).
Limulus assay (HI, IV)
The endotoxin contents of LF or peptides and the capacity of the peptides to neutralize LPS 
and lipid A were analysed by Limulus Amoebocyte Lysate assay (LAL) using a kit from 
Chromogenix. LF or peptides were solved in double distilled water (super Q) for endotoxin 
determination (III) or in Tris buffer (0.05M, pH 7.3) (IV). For the neutralizing activity 
determination, different concentrations of the peptides were incubated for 1 h at 37°C in 
pyrogen free tubes with 0.3 ng/ml LPS/lipid A. Two other LPS neutralizing agents 
(polymyxin B and a peptide based on the bactericidal/permeability increasing protein, BPI) 
were used for comparison (IV). The Limulus activity was analysed according to the 
manufacturer's instructions.
Microorganisms (I, IV)
E.coli DS17 of the serotype 06:K5:H- was used in the UTI animal model (I). The strain 
originates from a child with acute pyelonephritis and expresses type 1 and P fimbriae and 
hemolysin. Bacterial strains E. coli 014, E.coli 06K5 (DS 17) Klebsiella pneumonie (CCUG 
9997), Enterococcus faecalis (ATCC 19433); Staphylococcus epidermidis (CCUG 18000A), 
Staphylococcus aureus (CCUG 1800), and the yeast Candida albicans (ATCC 64549) were 
used in paper IV.
For UTI infection, the bacteria were cultured in Luria broth supplemented with 0.1% CaCl2 at 
37°C overnight or for two more days (I). For the microbicidal assay the microorganisms were 
cultured either as above (I) or all organisms were cultured in brain heart infusion medium 
(BHI) overnight at 37°C (IV). The bacteria were harvested by centrifugation, washed two 
times, diluted in PBS and adjusted spectrophotometrically to approximately 109 bacteria/ml (I, 
infection). For the microbicidal activity determination, a volume of the microorganism culture 
was transferred to a new tube with broth and incubated for two more hour at 37°C. 
Microorganisms were washed once and suspended in the broth used for microbicidal assay to 
a concentration of approximately 4xl06. The concentration of the bacteria was checked by 
viable counts.
Anti-microbial activity of LF or peptides (I, IV)
hLF, bLF or hLF peptides were serially diluted in medium. Different media were used 
depending on the experiment: BHI diluted 1:100 (I, IV), mouse urine (I) or 10 mM phosphate 
buffer pH 7.4 (I) or 1% bactopeptone (IV). The solutions (200 (il) were added to the 
microtiter plates (Nunclon, Nunc, Denmark). The microorganisms were added to the wells in 
a volume of 10 pi in order to give a final concentration of 2xl05/ml. The concentration of the
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stock solution was always checked by viable counts. The plates were incubated at 37°C in a 
humid chamber for 2 hrs. Thereafter 5 pi was taken from each well and added as a drop onto 
a blood agar plate and the plate was incubated overnight at 37 °C. The concentration of LF or 
peptides giving 99% reduction of the inoculum was defined as MMCV In some experiments 
the viable count of microorganisms were determined for each concentration of LF or hLF 
peptides after 2 h of inoculation with the microorganism (I).
Protocols of oral administration of LF and LF peptides to mice (I, II)
hLF, bLF and the peptides HLD1 and HLD2 were given to the animals with E. coli induced 
urinary tract infection (UTI) (paper I). hLF and the two peptides were given to mice with DX- 
induced colitis. LF or peptides were dissolved in double distilled (super Q) water or PBS and 
given to mice perorally with a pipette in a volume of 50 pi on the back of the tongue. LF and 
peptides were given in a dose of 500 pg/mouse at 30 minutes after the instillation of bacteria 
into the urinary tract in the UTI model. The control groups received pure vehicle (PBS, water, 
or BSA solution).
Two different protocols of oral administration of hLF and peptides were used in the DX- 
induced model. They differed with respect to the time at which hLF were given to the animals 
in relation to the start of the DX-exposure. The dose of hLF or hLF peptides was the same in 
both protocols. hLF or peptides were given twice a day, once in the morning and once in the 
afternoon in a dose of 2 mg/mouse till the end of the experiments. hLF was given either prior 
to the DX exposure (no less than 30 min) or on the third day of DX-exposure. The DX 
exposed control group was given water or BSA. The animals were killed after 2, or 7 days of 
DX exposure.
Experimental UTI (I)
C3H/Tif and C3H/HeN female mice at least 8 weeks old (Charles River, Margate Trent, UK 
and Bomholtgård Breeding and Research Center Ltd. Ry, Denmark) were used.
Prior to inoculation the urinary bladders of mice were emptied by gentle compression of the 
abdomen. The urine from each mouse was collected and cultivated on lactose-bromthymol 
blue agar plates in order to check the sterility. The presence of PMN cells in the urine was 
checked by microscopy. The animals with bacteriuria or leukocyturia (>20 PMN/ml) were 
excluded.
Mice were infected under ether or methophane anesthesia by inoculation of 100 pi solution of 
109 E.coli 06K5 bacteria/ml into the urinary bladder via a catheter (0.61 mm, Intramedic, 
Becton Dickinson, Sparks, Md.) attached to a 20-mm needle on a tuberculin syringe. 
Immediately after inoculation the catheter was gently withdrawn. The animals were killed 24 
h after infection by cervical dislocation. The number of PMN in the mouse urine was 
determined 2, 6, and 24 h after the induction of UTI.
Determination of bacterial counts in organs
The number of viable bacteria present in the kidneys and urinary bladders of mice with UTI 
was determined by culturing suspensions of organ homogenates on blue agar plates. After 
killing of animals, the organs were removed aseptically and homogenized in 5 ml PBS in
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disposable plastic bags. Serial 10-fold dilutions of 50 pi of organ homogenates were made in 
sterile PBS and 100 pi of each dilution were cultured on lactose-bromthymol blue agar plates. 
The plates were incubated overnight at 37°C. The bacterial concentration was expressed as 
colony forming units (CFU)/organ. The detection limit of the culturing was 100 bacteria per 
bladder or pair of kidneys.
E.coli adherence to mouse uroepithelial cells
Uroepithelial cells from uninfected mice were collected by centrifugation (400xg for 10 min 
at room temperature) of urine pooled from 30 mice (C3H/Tif or C3H/HeN). The sediment 
was washed once and suspended in PBS to a concentration of 10^cells/ml. A mixture of 200 
pi of 109 CFU/ml of E. coli 06K5 bacteria suspended in PBS, 200 pi of uroepithelial cell 
suspension, and 100 pi of bLF, hLF, HLD1, HLD2 (10 mg/ml), or PBS was incubated on a 
rotator for 30 min at 37°C. After incubation, 3 ml of cold PBS were added and the cells were 
spun down, resuspended in PBS and fixed with one drop of neutral buffered formalin 
(Histofix; Histolab, Göteborg, Sweden). In one experiment with uroepithelial cells from 
C3H/HeN mice various concentrations of bLF (10, 5, 2.5 and 1,25 mg/ml) were first mixed 
with bacteria incubated on a rotator for 30 min at 37°C and thereafter with the uroepithelial 
cells. The mixture was incubated for 1 hr at 37°C with end over rotation and thereafter 
washed by repeated cycles of centrifugation and resuspension in PBS. The number of bacteria 
attached to at least 20 cells was determined. Adhesion was scored with an interference 
contrast microscope (Nicon Optiphot, at 500x magnification). The adherence value was 
defined as the mean number of adherent bacteria per cell.
Hemagglutination
The ability of LF and peptides to affect bacterial type P or type 1 fimbriae mediated 
hemagglutination of human or guinea pig erythrocytes, respectively was determined by 
hemagglutination assay.
Twenty five pi of twofold serially diluted solutions of bLF, hLF, HLD1 and HLD2 (10 mg/ml 
initial concentration) in PBS were mixed with 25 pi of E. coli 06K5 bacteria suspended in 
PBS at a concentration of 109 or 2xl09/ml in 96-well microtiter plates (U-shaped, Greiner, 
Laborteknik, Kebo, Sweden). The plates were shaken at room temperature (RT) for 30 min. 
Then, 25 pi of erythrocytes (washed three times and resuspended at a concentration of 2% in 
PBS) were added. The plate was shaken and incubated for 2 hrs at room temperature. 
Hemagglutination was read by eye and by bright-field microscopy at x40 magnification.
Bacterial agglutination
The ability of LF or peptides to agglutinate E.coli 06K5 bacteria through interaction with 
type 1 fimbriae was analized by an agglutination assay. Twenty five pi of bLF, hLF, HLD1, 
and HLD2 at a concentration of 10 mg/ml was serially diluted twofold in the microtiter plate. 
An equal volume of PBS or a-merizyl-D-mannoside (25 mg/ml in PBS) and 50 pi of an E. coli
06K5 bacterial suspension (lxlO9) were added. The plate was shaken and incubated at 37°C 
for 30 min and then kept at 4°C overnight. The agglutination was read by eye and by bright-
29
field microscopy at x40 magnification. The reciprocal of the highest dilution rate giving 
bacterial agglutination was defined as the agglutination titer.
Dextran-sulphate-induced colitis in mice (II)
C57B1/6J male mice at 8 weeks of age (Bomholtgård Breeding and Research Centre) were 
used.Acute colitis was induced by giving 5% dextran sulphate (DX) (TdB Consultancy, 
Uppsala) in the drinking water. DX with MW of 40-44 kDa and a sulphur content of 15-17% 
was used. Fresh DX solutions were prepared daily, and the pH was adjusted to 8.5. Animals 
were given DX for either 2 or 7 days. At the end of the experiments the animals were killed 
by cervical dislocation. The presence of occult blood was evaluated in the faeces of animals 
with DX-induced colitis by using a hemocult test (Bergman&Beving, Mölndal, Sweden). The 
animals were also inspected for macroscopic rectal bleeding.
Histology of colonic mucosa
The colon was removed, washed gently, divided into 3 segments (distal, middle and proximal) 
and each segment into two parts (one part was used for histology, one for 
immunohistochemistry, see below). The part for histology was fixed in 4% neutral buffered 
formalin, embedded in paraffin, sectioned and stained with hematoxylin-eosin. The following 
scoring system was applied: score 0: intact crypt; score 1: loss of the basal third of the crypt; 
score 2: loss of the basal two thirds of the crypt; score 3: loss of the entire crypt with the 
surface epithelium remaining intact, score 4: loss of both the entire crypt and surface 
epithelium (239). The severity of colitis was estimated by measuring the areas with different 
scoring using a Leica microscope (Leitz, DMRB) connected to a computerized image-analysis 
system (Leica Q500 MC, Cambridge, UK). The evaluation was done blindly. The percentage 
of the damaged area to the total mucosa area was multiplied with its score and added together 
to a final score of the section.
Immunostaining and immunofluorescence (II, III)
Colon tissue (II)
Sections (5pm) of the frozen-Tissue Tek-embedded segments were made transversely using a 
cryostat (1720 Digital, Leitz), fixed in cold acetone (50% acetone for 30 seconds and then 
100% for 5 minutes) and then air dried for 1 hr. The fixed sections were kept at -70°C in 
aluminium foil until stained. Depletion of endogenous peroxidase activity was performed on 
the sections for 20 minutes at room temperature with a solution of 1 U/l glucose oxidase 
(Sigma), 10 mM glucose, and 1 mM NaN3. The sections were incubated for 15 minutes with 
avidin (Vector Labs, Burlingame, CA) followed by washing three times with PBS for 5 
minutes and incubation for 15 minutes with biotin (Vector Labs) in order to block the 
endogenous avidin-biotin-binding-activity. After washing three times with PBS for 5 minutes, 
the slides were incubated overnight at 4°C with primary monoclonal antibodies diluted in 
PBS-Tween with 2% BSA and 2% goat serum (30 p 1/section). The following monoclonal 
antibodies were used: F4/80 (F4/80 macrophage antigen, clone CLA3-1, Serotec, Oxford, 
UK); L3T4 (CD4, clone RM4-5, Pharmingen, San Diego, USA); Ly-2 (CD8, clone 53-6.7, 
Pharmingen) and biotinylated mouse anti-mouse I-Ab (clone AF6-120.1, Pharmingen) diluted
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at 5 (ig/ml. Purified rat IgG2b (clone LO-DNP-11, Serotec) and IgG2a, K, (clone P35-95, 
Pharmingen) in the same concentrations as the primary antibodies were used as isotype 
controls. Tissue sections were washed 3 times with PBS for 5 min between each step of 
incubation. For F4/80, CD4 and CD8 staining, the sections were incubated for one hour with 
the secondary biotinylated polyclonal goat anti-rat IgG antibodies (mouse IgG absorbed, 
Pharmingen, 2.5 (ig/ml) diluted in PBS-Tween with 2% BSA. The slides were thereafter 
incubation with avidin-conjugated-peroxidase (ABComplex, Dako, Danmark) followed by 
with the peroxidase substrate solution consisting of 3-amino-9-ethyl-carbazole (Sigma) and 
H202 for 5 minutes. All sections were counter stained with Mayer's hematoxylin for 5 
minutes and mounted with Aquamount improved (BDH, Laboratory, Poole, England). The 
number of positively stained cells were evaluated by microscopy (Leitz, DMRB) connected to 
a computerised image-analysis system (Leica Q500 MC). The slides were analysed blindly. 
At least five randomly selected fields of each tissue segment were counted. F4/80 in 
submucosa, CD4 and CD8-positive cells were expressed as number of cells/area of tissue, 
while MHC class II (I-Ab) and F4/80 expression in the mucosa was recorded as the stained 
tissue area divided with the whole measured area x 100%.
The procedure for staining the cytokine positive cells in the colon tissues was similar as the 
protocol described above with some exceptions. The sections were fixed at 4°C for 8 min with 
a freshly prepared 2% paraformaldehyde in PBS. The endogenous peroxidase was blocked 
with 1% H202. Eagle buffered salt solution (EBSS) containing 0.1% saponin was used to 
prepare the washing buffer, the endogenous peroxidase and biotin blocking solutions, and to 
dilute the antibodies.
Saponin is a plant glycoside with high affinity for cholesterol and was used in order to allow 
the cytokine antibodies to penetrate through the cell surface membrane, the cytosol, and the 
membranes of the endoplasmic reticulum and the Golgi organelle. The permeabilization 
induced by saponin is reversible, therefore it is important to add it to all the incubation and 
washings steps. The following monoclonal antibodies were used for cytokine staining: rat 
anti-mouse TNF-a (IgGl, clone MP6-XT22, Pharmingen) and rat anti-mouse IL-10 (IgG 1, 
clone JES5-2A5, Serotec) diluted to a concentration of 5 (ig/ml.
LF in monocytes (III)
The intracellular localization of exogenous LF in human monocytic cells was analyzed by 
immunostaining using LF specific antibodies. THP-1 cells were either cultured on chamber 
slides and treated for 4 hrs with hLF at 37°C, or the cells were settled in 24 well plates and 
treated with LF for different time points (10, 30, 240 min) at 37°C. The controls were treated 
with cell assay medium instead. The chamber slides were washed with PBS and allowed to 
dry for 30 min at room temperature. The cells collected from 24 well plates were washed by 
centrifugation three times with cold PBS, and the cell pellet rapidly frozen in liquid nitrogen 
as described for colon tissue. The chamber slides or 5 (im cryostat sections of the cell pellet 
were fixed in cold acetone and stained as described above for colonic tissue. For staining the 
chamber slides the following antibodies were used: as primary antibodies mouse monoclonal 
antibodies to hLF (IgGl k) or isotype control mouse (Becton Dickinson) diluted at 8 (ig/ml in 
PBS-T containing 2% BSA and as secondary antibodies biotinylated F(ab')2 fragment of 
rabbit anti-mouse immunoglobulin (Dako, Denmark) diluted 1:400 in PBS-T containing
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2%BSA and 2% normal serum. For staining the cryostat sections of the cell pellets the 
following antibodies were used: affinity purified goat anti-bLF (Bethyl Laboratory, 
Montgomery, TX) and rabbit anti-hLF immunoglobulin fraction (Dako) diluted 1:50 in PBS- 
T containing 2% HSA or BSA. The slides were analyzed by light microscopy.
To confirm the nuclear localization of LF, the confocal fluorescence microscopy was used. 
Cells were treated with LF at 37°C in 24 well plates. The cells were washed with cold PBS 
(3x). Thereafter, cytospin preparation of cells were obtained and fixed for 60 min with 2% 
paraformaldehyde in PBS. For preventing non-specific binding, PBS-T containing 2% BSA 
and 10% rabbit serum was added to the slides for 20 min. After washing, the slides were 
treated with 0.2% Triton X-100 in PBS for 2 min in order to permeabilize the cell membrane. 
Incubation with 2% BSA and 10% rabbit serum was repeated. After washing, the slides were 
incubated for 2 hrs with FITC conjugated affinity purified F(ab')2 fragment of rabbit anti­
human lactoferrin diluted 1:50 in PBS-T containing 2%BSA (hLF staining) or goat anti-bLF 
(affinity purified, Bethyl Laboratories) diluted 1:100 in PBS-T containing 2% HSA (bLF 
staining). For bLF staining, after washing, the slides were incubated for 1 h with rabbit 
F(ab')2 anti-goat IgG-FITC labeled diluted 1:500 in PBS-T containing 2% HSA. The slides 
were washed in PBS, mounted in fluorescent mounting medium (Dako) and examined by a 
confocal microscope supplied with argon laser and equipped with an excitation filter set at 
488, 568 and 647 nm (Carl Zeiss, Germany). A series of 15 optical sections at 1 pm intervals 
were recorded through cells.
ELISA (I, II, III)
The method was used in order to quantify the levels of hLF in the serum and urine of mice (I, 
II), the cytokines in the serum of mice with DX-induced colitis (II), and the cytokine secretion 
in the cell supernatants of LPS-stimulated human monocytic cell lines (III).
The basic protocol for hLF and human cytokines determination was similar, with some 
exceptions. The primary and secondary antibodies used in different ELISAs are indicated in 
Table 4.
The plates (Maxisorb, Nunc, Denmark) were coated overnight either at 4°C or room 
temperature with the primary antibodies appropriately diluted in the dilution buffer (0.1 M 
bicarbonate buffer pH 9.6 or PBS pH 7.4 for hLF and cytokine determination, respectively). 
After washing with PBS containing 0.05% Tween (PBS-T), the plates were blocked with the 
blocking buffer (5% fish gelatin in PBS or 1-5% BSA in PBS for hLF and cytokine 
determination, respectively) at room temperature for 1 or 16 hrs, depending on the protocol. 
For IL-10 and IL-12 determination the plates were left to dry at room temperature overnight 
after blocking. Thereafter, the samples and the standards appropriately diluted in the sample 
dilution medium (1% fish gelatine in PBS-T or cell assay medium consisting in RPMI 1640, 
5% FCS and 1% pest) were added to the plates in duplicates. The biotinylated secondary 
antibodies diluted in 1% BSA in PBS were added together with the samples for the IL-10 and 
IL-12 determinations. The plates were incubated for 2 hrs at room temperature and then 
washed. For hLF determination alkaline phosphatase conjugated antibodies diluted in 1% fish 
gelatine in PBS-T were added. For cytokine determination (except IL-10 and IL-12), 
biotinylated secondary antibody appropriately diluted in 2% BSA in PBS were added. The
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plates were incubated overnight at 4°C. After washing, the plates were incubated with the 
alkaline phosphatase substrate for hLF determination.
Table 4. Antibodies used in ELISA
antigen primary clone company cone. sample secondary company cone. detection sensitivity study
antibodies (Hg/ml) dil. antibodies (Ug/ml) enzyme of the assay
hLF rabbit Dako 18 undiluted alkaline ICN 0.6 1.5 ng/ml m
anti-hLF 1:2 phosphatase
(IgG fraction) conjugated
rabbit anti-hLF
Human
cytokines
IL-lß mono 6217.111 R&D 4 1:2 biotinylated R&D 0.1 alkaline 16 pg/ml m
clonal Systems 1:4 polyclonal Systems phosphatase
mouse 1:20 goat
anti human 1:40 anti human
IL-lß IL-lß
TNF-a mono 28401.111 R&D 4 1:2 biotinylated R&D 0.2 alkaline 16 pg/ml m
clonal Systems 1:4 polyclonal Systems phosphatase
mouse goat
anti human anti human
TNF-a TNF-a
IL-6 mono 6708.111 R&D 4 1:2 biotinylated R&D 0.025 alkaline 16 pg/ml in
clonal Systems 1:4 polyclonal Systems phosphatase
mouse 1:20 goat
anti human 1:40 anti human
IL-6 IL-6
IL-8 mono 6217.111 R&D 4 1:25 biotinylated R&D 0.02 alkaline 32 pg/ml HI
clonal Systems 1:50 polyclonal Systems phosphatase
mouse goat
anti human anti human
IL-8 IL-8
IL-10 mono B-N 10 Diaclone 1:100 1:2 biotinylated Diaclone 1:50 horseradish 16 pg/ml in
clonal dil monoclonal dil peroxidase
mouse anti humaan
anti human
IL-10
IL-10
IL-12 mono B-T10 Diaclone 1:400 1:2 biotinylated Diaclone 1:50 horseradish 16 pg/ml m
clonal
mouse
anti human
IL-12
dil dil peroxidase
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For cytokine detection, the plates were incubated for 20 minutes with either horseradish 
peroxidase conjugated streptavidin (diluted 1:6700 in 1% PBS-T, IL-10 and IL-12) or alkaline 
phosphatase conjugated extravidin diluted 1:1000. After washing 4 times, the substrates for 
alkaline or horse radish peroxidase, respectively (1 mg/ml p-nitrophenyl phosphate in 10 
mmol/1 diethanolamine, 0.5 mmol MgCl2, pH 9.5 or tetramethylbenzidine) were added to the 
plates. The color development was either read in a microplate reader (Multiskan Bichromatic, 
Labsystem, Göteborg, Sweden) at 405 nm or the reaction was first stopped with 1 M H2S04 
and then read at 450 nm.
Mouse serum samples were analysed for IL-lß, TNF-a, IL-6, IL-10 and IL-12 using ELISA 
kits (R&D system and Biosource International, Camarillo, CA) according to the 
manufacturer's protocols. Serum samples were diluted 1:2. The detection limit for these 
cytokines were 8 pg/ml for IL-1 ß, 15 pg/ml for IL-12, 30 pg/ml for IL-6 and IL-10, and 47 
pg/ml for TNF-a.
IL-6 determination by bioassay (I, III)
The method was used to measure IL-6 levels in urine and serum of animals with UTI, and IL- 
6 secretion in the supernatants of LPS-stimulated THP-1 cells (I, III). B9 hybridoma cell line 
which is dependent on IL-6 for growth was used. The cells were harvested from the tissue 
flasks and seeded into microtiter plates at the concentration of 5000 cells/well. Samples or IL- 
6 standard (Genzyme Corporation Cambrige, MA) were added to the cells and incubated for 
72 hrs in Iscove's modified Dulbecco's medium supplemented with 5x10'5 M ß- 
mercaptoethanol and 5% fetal calf serum (FCS). 3H-thymidine was added 4 hrs before 
harvesting the cells. One unit of IL-6 per ml was required for half-maximal proliferation of 
B9 cells (approximately equivalent to 1 pg).
Cell assay (HI)
The ability of LF to affect the LPS-induced cytokine production was investigated in two 
human monocytic cell lines (THP-1 and Mono Mac 6) which were stimulated with E. coli 
LPS (055:B5). THP-1 was obtained from ATCC (Manassas,VA, USA) and maintained in 
RPMI 1640 medium supplemented with 10% heat-inactivated FCS (GIBCO, BRL, Life 
Technologies INC , Gaitesburg, MD), 1% sodium pyruvate (Gibco) and 2.5% HEPES 
(Gibco). Mono Mac 6 was obtained from DSM (Braunschweig, Germany) and maintained in 
RPMI 1640 supplemented with 10% heat-inactivated FCS, 1% sodium pyruvate, 1% L- 
glutamine, 1% bovine insuline and 1% non essential amino sugars (Gibco). The cells were 
maintained at 37°C in a 5% C02 incubator. The two cell lines differed with respect to the 
maturity. THP-1 cells are less matured, expressing low levels of CD 14 and MHC class II on 
the cell surface, while Mono Mac 6 cells are more matured, expressing higher levels of CD14 
and MHC class II. The THP-1 cells were prestimulated for 16 hrs with 100 U/ml IFNy
(human recombinant, produced in E. coli >99% pure, endotoxin levelclOEU/lxlO^U, 
Boehring Mannheim Biochemica, Mannheim, Germany) in order to increase the sensitivity to 
LPS. For the cell experiments, the cell density was adjusted to lxlO^cells/ml in the cell assay 
medium (RPMI 1640 containing 5% FCS and 1% pest) and 400 pi were added to 24 well-
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plates. The cells were allowed to settle for 1 hr in the cell incubator and thereafter stimulated 
with 5-10 ng/ml of LPS (E. coli serotype 055:B5; Sigma Chemical CO., St. Louis, Mo) for 
different time points (0, 1, 2, 4, 6, 12 and 18 hrs). Thirty minutes before or after the LPS 
addition, the cells were given LF. In one experiment, the cells were stimulated with 250 ng/ml 
recombinant IL-lß (rIL-lb, R&D systems, Abingdon, UK). The viability of the cells in the 
presence of LPS or/and LF ranged within 85-95% as measured by trypan blue exclusion.
Reverse transcriptase PCR (RT-PCR) (III)
The cytokine mRNA expression was analysed by a semiquantitative RT-PCR. A 
simultaneuosly amplified sequence of the housekeeping gene glyceraldehyde-3-phosphate 
dehydrogenase (G3PDH) was used for comparison. The total RNA was extracted from the 
cell pellets with a ready to use reagent, which contained phenol and guanidinium thiocyanate 
in a monophase solution (RNA STAT-60, Tel-Test"B" Inc.; Friendswood, TX, USA). After 
being extracted with chloroform, precipitated with isopropanol and washed with ethanol 
according to the manufacturer's instructions, the RNA was treated with RNase-free DNasel 
(Promega, Falkenberg, Sweden), in order to remove the genomic DNA. The yield and purity 
of RNA was quantified by measuring the ratio of the optical density at 260 and 280 nm. 
Successful isolation of undegraded RNA was monitored by minigel electrophoresis in 3% 
agarose in the presence of ethidium bromide and identification of the 28S and 18S ribosomal 
RNA bands.
One pg of extracted RNA was used for cDNA synthesis in a 30 pi reaction mix containing 3.3 
mM random hexamer primer (pd(N)6; Amersham Pharmacia Biotech, Sweden), lxRT buffer 
(GIBCO) 0.5 mM dNTP (dATP, dCTP, dGTP and dTTP; Amersham Pharmacia Biotech), 
lU/ml human placenta RNAase inhibitor (Promega) and 13.3U/ml reverse transcriptase 
(Superscript;GIBCO), and diethyl pyrocarbonate-treated water (DEPEC-H20). The reaction 
was carried out at 42°C for 60 min. After synthesis, samples were stored at -70°C until the 
PCR amplification. For each cytokine, commercially available specific primers, positive and 
negative controls (Clontech Laboratories, Palo Alto, CA, USA) were used for PCR 
amplification. The housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (G3PDH) 
was simultaneously amplified. Commercial available primer pairs for cytokines were used. 
Two pi of cDNA were added to a reaction mixure with a final concentration of IX PCR II 
(Perkin Elmer), 2mM of MgCl2, 0.2 mM of each dNTP, 0.4 mM of each primer and 1.25U 
Taq polymerase (AmpliTaq gold; Perkin Elmer) in a final volume of 50 pi. The PCR profile 
used was dénaturation at 94°C for 45s, annealing at 60°C for 45s, and extension at 72°C for 2 
min (Gene Amp PCR system 9600, Perkin Elmer). The gene products were separated by 
electrophoresis in 3% agarose gel containing ethidium bromide. The gels were photographed 
in UV light by a polaroid camera. IPLab Gel software was used for densitométrie analysis of 
the bands of the scanned gel images. The levels of cytokine mRNA were expressed as the 
ratio between the cytokine and the G3PDH gene products for each sample.
Preparation of nuclear protein extracts (HI)
Cells were harvested on ice after 1 or 2 hrs of stimulation with LPS and washed two times by 
centrifugation (300g, 5 min) at 4°C with cold PBS. Hypotonic buffer (1.5 ml containing 10
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mmol/1 HEPES pH 7.9, O.lmmol/1 EGTA, 10mmol/KCl, 2.5mg/ml BSA, 
O.75mmol/spermidine, Sigma, 0.15 mmol/1 spermine, Sigma, Complete ™ proteinase 
inhibitors, Roche Diagnosics, Mannheim, Germany, and 1 mmol/1 DTT, Roche Diagnostics) 
was added to the cell pellet. The cells were homogenized on ice by 8 strokes with a B pestle 
in a Dounce homogenizer. Cell nuclei were collected by centrifugation at 16000 g at 4°C for 
10 min. The nuclei were resuspended in 60-100 pi of elution buffer (20 mmol/1 HEPES pH 
7.9, 25% glycerol 0.42 mol/1 NaCl, 1 mmol/1 EDTA,lmM/l EGTA, lmmol/DTT) 
supplemented with the same proteinase inhibitors as in the hypotonic buffer. After extraction 
for 45 min at 4°C, the nuclear proteins were separated from nuclei by centrifugation at 16000 
g at 4°C for 1 h. The supernatant containing the proteins, was collected and stored in aliquots 
at -70°C. Protein concentrations of the nuclear extracts were measured according to Bradford 
using a protein assay kit (Pierce, Stockholm, Sweden). Bovine serum albumin was used as a 
protein standard.
Electrophoretic mobility shift assay (EMSA) (III)
The ability of LF to interfere with NF-kB binding to the TNF-ot promoter was analyzed by 
EMSA. Nuclear protein extracts were analyzed by EMSA for their ability to bind to a specific 
a32P labeled oligonucleotide, corresponding to the sequence -646 to -613 on the human 
TNF-a promoter containing a binding site for the transcription factor NF-kB. The 
protein-DNA binding reaction was carried out in a volume of 20 pi containing 20 mM Tris- 
HC1, pH 7.9, 75 mM NaCl, 0.1 mM EGTA, ImM DTT, 5% glycerol and 5 pg of poly (dl- 
dQpoly (dl-dC), (Amersham Pharmacia Biotech, Sweden). Approximately 70,000 Cerenkov 
cpm corresponding to 2 ng of the probe and equal amounts of nuclear protein extracts were 
added to each reaction mixture and allowed to proceed for 30 min at room temperature. The 
reaction mixtures were then separated by electrophoresis through a native 5% polyacrylamide 
gel containing 0.25X TBE (2.2 mmol/1 tris borate, 2.2 mmmol/1 boric acid, 0.5 mmol/1 
EDTA) and 3% glycerol, to distinguish DNA-protein complexes from unbound DNA probe.
Statistics
Differences between groups were analysed for significance by either non parametric Kruskal 
Wallis test followed by Dunn's post test for multiple comparison (II), or ANOVA test followed 
by Bonferoni post test for multiple comparison (III) when more that 2 groups were compared. 
Mann-Whitney U-test was used when two groups were compared (II). This test was also used in 
I. Frequencies were analyzed by Fisher's Exact test (II). Differences were considered significant 
for values of p<0.05.
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RESULTS AND DISCUSSION
Orally given hLF and peptides based on the antibacterial region of hLF are 
active against experimental E.coli UTI in mice (I)
The effect of orally given LF and peptides based on the anti-bacterial region of hLF (HLD1 
and HLD2) on the infection and inflammation induced at a remote site from the gut, the 
urinary tract, was investigated in this study.
LF or peptide treatment was initiated 30 min after the induction of UTI. Since in vitro studies 
showed a more potent antibacterial effect of bLF than hLF, two mouse strains were used in 
the first series of experiments for bLF treatment (C3H/Tif and C3H/HeN) for comparing the 
effects in similar, but not identical strains. The hLF effect was assessed only in C3H/Tif mice. 
The number of bacteria present in the kidney and urinary bladder 24 hrs after infection was 
significantly reduced in LF treated animals compared to the control. Twenty nine and fifty 
seven percent of the animals in the hLF treated group had no detectable bacteria in the 
kidneys and bladder respectively, but none in the control group (Figs. 1 a and 2 a, I). The 
corresponding figures for the bLF group were 14 and 35 percent respectively, in the C3H/Tif 
mice and 11 and 39 in the C3H/HeN mice (Figs 1 and 2, I). The inflammatory parameters 
(number of PMN and IL-6 levels in the urine as well as IL-6 in the serum) were also reduced 
in the LF treated animals compared to the controls (Figs. 3,4, and 5,1).
Since the overall results of the first series of experiments showed that hLF was somewhat 
more efficient than bLF in reducing the infection and inflammation in the urinary tract, 
synthetic peptides based on the antibacterial region of hLF were compared with hLF in the 
next series of experiments. The results showed that the linear peptide HLD2 was as effective 
as hLF in reducing the number of bacteria in the kidney (Table 2, I). A similar pattem was 
seen for HLD1 although protection was not quite significant (Table 2,1).
A summary of the main effects of LF and peptides on the parameters analyzed is shown in 
Table 5.
The next question asked was if hLF is taken up into the circulation and transported to the 
urinary tract, exerting its activity locally. The analysis of hLF in the serum by ELISA showed 
that it was present in the serum of 11 out of 24 animals treated with hLF, but not in those 
treated with the vehicle, indicating that the protein can pass over to the circulation (data not 
shown). Moreover, by ELISA, hLF was found in the urine of uninfected mice given hLF (Fig. 
5). Thus, hLF effects could be mediated locally.
Next, the possible mechanism of the hLF effects in the urinary tract was addressed. Since 
adherence of bacteria to the uroepithelial cells is the first step in the pathogenesis of UTI, the 
interference of LF with this activity was investigated. Agglutination of bacteria by bLF has 
been reported and thus this aspect was also investigated. hLF or the peptides affected neither 
adherence nor agglutination of bacteria. However, the mannosylated bLF blocked the 
adherence of E.coli by 50% and bacterial agglutination via binding to type 1 fimbriae (data 
not shown). This indicates that the interference with mucosal adherence of bacteria is not the 
mechanism responsible for the anti-infectious effects of hLF or peptides.
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Table 5. The effects of LF or peptide treatment on the parameters analyzed in UTI compared 
to the control.
No. of bacteria present No of IL-6 IL-6
in the urinary tract PMN levels levels
24 hrs after inoculation in urine in urine in serum
treatment kidneys bladder 2 6 24 hrs 2 6 24 hrs 24 hrs
hLF ^b.c * (*) 4" no no At
HLD1 no n.d. n.d. no n.d. n.d. n.d. n.d.
HLD2 (*)' no n.d. n.d. no n.d. n.d. n.d n.d.
bLF A>{ no no 4^j no no no
At, significantly reduced parameter; (*), reduced, but not significant; no, parameter not 
changed; n.d. not done; a29 and 25% of animals free of detectable bacteria in the first and 
second series of experiments, respectively;b 57% of the animals free of detectable bacteria in 
the first series of experiments ;c’ not significantly reduced in the second series of experiments, 
however the inflammatory response of the host was reduced in these experiments compared to 
the first series;d 17% of the animals free of detectable bacteria; ' 16% of the animals free of 
detectable bacteria/14 and 11% of animals free from detectable bacteria in the C3H/Tif and 
C3H/HeN groups, respectively ; 8 35 and 39% of the animals free of detectable bacteria in 
C3H/Tif and C3H/HeN, respectively; hnot significant in the second series of experiments;1 
only reduced in C3H/Tif, but not in C3H/HeN mice;j reduced only in C3H/Tif, but not in 
C3H/HeN mice.
Urinary hLF
40‘
£ 30-
hours
-•«-hLF:0,5 mg 
—*-hLF:4 mg 
—control
Fig. 5. Levels of hLF in the urine of C3H/Tif mice treated perorally with hLF. The bars represent the 
mean and standard error of urinary hLF levels in four to six animals per time point.
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Fig. 6. Concentration o/E.coli 06K5 bacteria in undiluted urine and phosphate buffer in the presence 
of hLF, bLF, HLD1 or HLD2 after 2 hrs of incubation The concentration of bacteria in the inoculum 
was 2x10s CFU/ml and the number of bacteria in the controls were 1.4x10s and 2.2x10s CFU/ml.
A 60% reduction of the bacterial number was observed in undiluted urine in the presence of 
HLD2 compared to the control after 2 hrs of incubation (Fig. 6). Urine by itself had a 
bacteriostatic and bactericidal effect on bacteria. Both HLD1 and HLD2 killed 100% of the 
inoculum in the phosphate buffer (Fig. 6). hLF and bLF reduced the concentration of bacteria 
to 18 and 2% respectively.
The results indicated that hLF is effective in reducing infection and inflammation in the 
urinary tract. The effects are possibly mediated by the hLF or peptides locally. The 
bactericidal activity of hLF, or fragments thereof is suggested as a possible mechanism. The 
bactericidal activity of the peptides are affected by the salt concentration. Therefore, it is 
possible that the milieu of the renal tubuli with a low salt concentration might be the site were 
the peptides are the most effective against bacteria. Whether the intact hLF molecule or 
fragments thereof is the main component reaching the circulation has not been elucidated. It is 
not excluded that the mechanism by which hLF exerts its effects may be multifactorial. Since 
anti-bacterial and anti-inflammatory activities have been described for hLF in vitro it is 
possible that both of these properties also act in vivo (163). Thus, the anti-inflammatory 
activity could be either a consequence of the anti-bacterial effect or the downregulation of IL- 
6, or both.
Anti-inflammatory activities of hLF in acute DX-induced colitis in mice (II)
The anti-inflammatory activities of hLF in vivo were investigated using a model of 
inflammation of the gut. Acute colitis was induced in mice by giving DX in the drinking 
water for either 2, or 7 days. Oral administration of hLF and peptides was initiated either 
before or after an inflammation had been established , e.g., on the third day of the DX 
exposure. In the control group the hLF or peptide solution was replaced by solely vehicle. The 
appearance of blood in the faeces was delayed and partly reduced in the hLF treated animals 
(Figs. 1 a, b, and 2 a, b, II). The shortening of the colon, a pathological effect of the DX 
exposure, was reduced in the hLF treated animals compared to the control (Figs. 1 c. Table 2, 
II). Treatment with hLF starting on the third day of the DX exposure also resulted in
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diminished bleeding and contraction of the colon. Also the IL-lß levels in the blood were 
significantly diminished in the hLF treated group compared to the control (Fig. 1 d, II). A 
significantly reduced crypt score and reduced numbers of CD4+, F4/80 positive macrophages, 
and TNF-a producing cells were detected by histology and immunohistochemistry in the 
distal colon of hLF treated animals after 7 days of DX exposure (Fig. 2 c, II, and Fig.7). The 
HLD1 and HLD2 gave almost identical results to those of hLF concerning the clinical 
parameters after two days of DX exposure (Fig. 1, II). A summary of the effects of orally 
given hLF or peptides in the acute colitis is presented in Table 6.
Table 6. The effects of hLF or peptide treatment on the clinical parameters in DX induced 
colitis compared to the control.
DX
exposure
(days)
treatment occult
blood
macroscopical
rectal
bleeding
colon
length
serum
IL-lß
crypt score
distal colon
2 hLF (*) (*) (t) At noa
HLD1 (*) (*) t At noa
HLD2 * (*) t At noa
7 hLF n.d no A>
hLF* n.d. * * n.d. n.d.
At significantly reduced parameter; (*). reduced, but not significant; no, parameter not 
changed; n.d. not done;a no significant damage in the colon after 2 days of DX exposure;b 
hLF treatment started on the third day of DX exposure; * fewer hemocult positive mice during 
the first 3 days of DX exposure, and significant only on day 2 of DX exposure ”fewer mice 
with macroscopical rectal bleeding on days 3, 4 and 6 of DX exposure, and significantly 
fewer on day 4.
hLF was detected in the serum of animals perorally treated with hLF, but not in the controls 
(Table 1, II), indicating that the protein can reach the colon not only via the gut, but also 
through the circulation. The histopathological damages induced by DX in the colon consisted 
in epithelial exfoliation and infiltration of inflammatory cells. The damages induced by DX 
were more pronounced after seven days in the distal and middle parts of the colon, while the 
proximal part was less affected. The effects of hLF on the length of the colon and the 
improved crypt score could be due to its reported ability to stimulate the proliferation of 
epithelial cells (255). Although the role of bacteria in the initiation of DX-induced colitis 
model is debated, there is a shift in the normal bacterial flora (251, 252). Thus, increased 
numbers of the Clostridium species, Bacteroidaceae and Enterobacteriaceae were detected in 
the faeces of mice exposed to DX (234). This may have some bearings on the development of 
the disease. A contribution of bacteria and bacterial products in the severity of the later phase 
of the DX induced colitis was reported (240).
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Fig. 7. The number of F4/80-positive cells in the colonic mucosa (a) and submucosa (b), the number 
of CD4-positive cells (c), and TNF-a producing cells (d) in the colonic mucosa of mice treated with 
DX for seven days. The DX-treated mice were given hLF or water (controls). The boxes indicate the 
25'h, 50"' and 75,h percentiles and the bars the lowest and the highest values. 'p< 0.05, ** p<0.01, 
Mann Whitney U test.
Antibacterial activities against Clostridium spp. were reported for orally given bLF in vivo in 
a model of colonization of mice with these bacteria (127). Thus, it is possible that the 
antibacterial activities of hLF or peptides against members of Clostridium and Enterobacteria 
(E. coli) could have contributed to the reduced symptoms observed in the hLF or peptide 
treated mice compared to the controls.
The macrophages are suggested to contribute to the pathogenesis of the DX-induced colitis 
(234, 248). An increased number of these cells (F4/80 positive) was detected in our study in 
the colonic mucosa and the submucosal oedema after seven days of DX exposure compared to 
DX-unexposed animals (Fig. 3 a, II and data not shown). The increased number of F4/80 
macrophages in the colonic mucosa has also been reported by others (244). The macrophages 
may secrete cytokines which contribute to the tissue damage (244-247). A lower number of 
F4/80 positive macrophages was found in the middle part of the colon of the hLF- and HLD1 
treated groups after 2 days of DX exposure compared to the control (Fig. 1 e, II). The hLF 
treatment also significantly reduced the number of infiltrating F4/80 macrophages in the 
colonic mucosa and submucosa after seven days of exposure (Fig. 7 a, b). This finding 
correlated with a reduced number of TNF-a producing cells in the distal colonic mucosa (Fig. 
7 d) and IL-10 producing cells in the submucosa oedema of the middle part of the colon of the 
hLF treated mice compared with controls (data not shown).
hLF treatment reduced the number of CD4-positive cells, either by a indirect or direct 
mechanism. Althougth the CD 4 positive cells are not crucial for the induction of DX colitis,
41
the reduction by LF treatment may reflect a reduced immune response. In vitro studies have 
shown that hLF could inhibit proliferation and cytokine production of a CD4/TH1, but not of 
a TH2 cell line. This effect could posibly have some bearing on the observed reduction of 
CD4 positive cells.
In conclusion, hLF has anti-inflammatory activities in the colon and its bactericidal region 
may contribute to these activities.
Lactoferrin down-regulates the LPS-induced cytokine production in 
monocytic cells via NF-kB (III)
Our in vivo studies showed that hLF is mediating anti-inflammatory activities in the colon and 
urinary tract (I, II). LPS induced host effector mechanisms have reported to contribute to the 
severity of the disease in the later phase of DX induced colitis (240). LPS is a potent inducer 
of inflammation in the urinary tract (223). In vitro studies have demonstrated that LF down- 
regulates the LPS-induced IL-lß, TNF-a and IL-6 cytokine production in monocytic cells 
(145, 163, 164). The mechanism by which LF is inhibiting the LPS-induced cytokine 
production in THP-1 and Mono Mac 6 monocytic cell lines was studied in paper III, by 
investigating the effect of LF on cytokine mRNA expression and the involvement of NF-kB. 
LF inhibited the LPS-induced cytokine production in a monocytic cell lines in a dose 
dependent manner and regardless of the time at which LF was added to the cells in relation to 
LPS (30 min before or after) (Fig. 1, III and Figs 8, 9).
TNF-a TNF-a
6 hr» 18 hr»
Fig. 8. Dose-inhibitory activity ofLF on LPS-induced TNF-a secretion in Mono Mac 6 cells. hLF (50, 
100, 200 pg/l(f cells) or hLF (50, 100, 200, 500 pg/l<f cells) were added to the cells 30 minutes 
before (bLF+LPS or hLF+LPS), or after (LPS+bLF or LPS+hLF) the addition of LPS (5 ng/lCf 
cells). The results are expressed as percentage of maximal response. The mean±SEM from three 
separate experiments are indicated. *’*p<0.01, ANOVA test followed by Bonferoni test for multiple 
comparison. The statistical significance for the highest dose ofLF versus control is indicated.
LF inhibited the LPS-induced secretion of TNF-a to 82-85% of the response, IL-6 to 56-68%, 
IL-lß to 44-64%, and IL-8 to 20-34 % in THP-1 cells at 18 hrs (Table 1, III). This inhibitory 
effect was obtained with a dose of 50 and 200 jig/ml for bLF and hLF. Increasing the 
concentration to 200 and 500 ug/ml for bLF, and hLF respectively, did not significantly
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increase the inhibitory effect.
Fig. 9. The effect of LF on IL-6 (a,b), IL-8 (c, d), IL-lß(e, f) and IL-10 (g, h) secretion in the 
supernatants of Mono mac 6 cells. Cells were given bLF (200 pg/Hf cells) or hLF (500 pg/106 cells) 
30 minutes before (bLF+LPS or hLF+LPS) or after (LPS+bLF or LPS+hLF) the addition of LPS (5 
ng/lCf cells). The results are expressed as percentage of the maximal response. The means±SEM from 
three separate experiments are indicated. ***p< 0.001.
The effect of LF on cytokine secretion was similar when monitored in a more mature 
monocytic cell line, Mono Mac 6 (Figs. 8, 9). The dose of LF needed to inhibit the LPS- 
induced TNF-a secretion to 70-80% was 200 and 500 pg/ml for bLF and hLF, respectively 
(Fig. 8). At these doses LF also inhibited the IL-6, IL-8, IL-lß and IL-10 after 6 and 18 hrs. 
Since the cytokines are mostly regulated at the transcriptional level, the effect of LF on 
cytokine mRNA expression was further investigated in THP-1 cells. By a semiquantitative 
RT-PCR method a lower level of LPS-induced TNF-a, IL-lß, IL-6 and IL-8 mRNA was
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detected at the peak of expression in THP-1 cells treated with bLF (Fig. 10).
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Fig. 10. The effect of bLF on LPS-induced mRNA expression (a, c, e, g) and the kinetics of cytokine 
secretion (b, d, f h) in THP-1 cells . Cells were given bLF (50 pg/10 6) 30 minutes before or after the 
addition of LPS (10 ng/10 6 cells). The TNF-a (a), IL-6 (b), IL-8 (e) and IL-lß(g) mRNA expression 
was assesed by RT-PCR using G3PDH as a house keeping gene. The effects of bLF at the peak of the 
cytokine mRNA expression are presented (2 hrs in a, e, and g, 4 hrs in c). The results are expressed as 
a percentage of maximal response. The mean±SEM from three separate experiments are indicated. 
*p<0.05, **p<0.01. ***p<0.001.
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The reported binding of LF to LPS and the prevention of LPS binding to CD 14 receptor via 
competition with LBP could partly explain the inhibitory activity on cytokine production 
(105, 106, 109). However, inhibition was seen in our system both when LF was added to the 
cells before and after LPS. Moreover, it was previously shown that LF inhibits the TNF-a 
induced IL-6 secretion and in this study we noted the ability of hLF to inhibit the IL-lß- 
induced IL-6 secretion (163). These results suggested that LF may have a more general effect 
on cytokine transduction pathways. Several studies have shown that LF is taken up by 
monocytic cells (150,167-169). However, the fate of the protein and the effects intracellularly 
are not fully elucidated (150, 169, 256). Therefore, we followed the uptake of LF 
intracellularly by immunohistochemistry and fluorescence confocal microscopy. LF was 
detected in THP-1 cells as early as after 10 min of incubation and in the nucleoli after 30 min 
(Figs. 3, 4 and Table 3 in III).
Since NF-kB regulates the transcription of pro-inflammatory cytokine genes, the interference 
of LF with LPS induced activation of this transcription factor was further investigated. A 
decreased binding of NF-kB to the human TNF-a promoter was found by EMSA after 1 h of 
incubation with LPS when LF was added to the cells 30 minutes before LPS (Fig. 5 a, III). 
The response was dose dependent, a dose of 500 and 200, but not 50 p.g/106 cells of hLF 
decreased the DNA binding of NF-kB. The decreased LPS-induced binding of NF-kB by LF 
was also seen after 2 hrs of incubation with LPS irrespective of the time at which LF was 
added to the cells in relation to LPS (Fig. 11). LF by itself had no effect on the binding of NF- 
kB to DNA.
Fig. 11. The effect ofbLF on the LPS induced binding of NF-kB to oligonuleotides from human TNF- 
a promoter. Nuclear extracts from THP-1 cells untreated or treated with LPS for 2 hrs in the presence 
or absence of LF were analyzed by EMSA for binding to a32P labeled oligonuleotide from TNF-a 
promoter -646 -613.
The results suggest that LF inhibits the pathway leading to NF-kB translocation to the nucleus 
or has a more direct effect on the NF-kB in the nucleus. Competition between NF-kB and LF 
for binding to the TNF-a promoter is excluded, since no binding of LF to the oligonucleotides
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was found by EMSA. The decreased binding of NF-kB to the TNF-a promoter with increased 
concentration of LF suggested that LF may bind to NF-kB.
The fact that LF, within 2 hrs, down-regulated the LPS-induced cytokine gene expression by 
inhibition of NF-kB to DNA indicates that no new gene expression is necessary for this 
inhibition. In summary, LF inhibits the LPS-induced cytokine mRNA via interference with 
NF-kB.
Structure-activity relationship of the aß antibacterial region of hLF (IV)
The hLF derived peptides used in the experimental UTI and colitis models were based on the 
antibacterial domain located in the N-terminal end in an aß region (Fig 5). Peptides based on 
this region were synthesized and the structure-microbicidal activity relationship was 
investigated in vitro in study IV. The importance of the disulphide bridge (position 20-37) and 
helix like formation was analysed with respect to the antimicrobial activity. The length and 
role of single amino acids of the helix region required for expressing optimal microbicidal 
activity were assessed. Microbicidal analyses (99% killing) were performed by a microplate 
assay.
The cyclization via the disulphide bridge in HLBD1 (a.a residues 16-40) and HLBD3 (a.a. 
residues 19-38) increased somewhat the microbicidal activity against E.coli and 
S.epidermidis, but HLBD3 against S.aureus only (Table 1, IV). Downsizing of the peptide 
sequence corresponding to residues 14-31 starting from the N-terminal end showed that four 
sequences (a.a. residues 17-31, 18-31, 19-31, 20-31) were the overall most active peptides as 
analysed against 7 bacterial strains and C. albicans (Table 2, IV). An alanine-scan of the a.a. 
residues 20-31 (HLBD10), showed that replacement of cysteine (Q-20 and tryptophan (W)- 
23 reduced the killing activity against the three analysed microorganisms (E.coli, S. aureus, 
and C. albicans) (Table 7). Replacing the arginine (R) residues at the end of HLBD10 
(positions 28 or 31) corresponding to the amphiphatic helical region also affected the killing 
activity, mostly against E.coli and C.albicans. Changing, however, W or R to the same type 
of a.a. (leucine, L or lysine, K) did not reduce the killing activity (Table 5 in IV). As 
expected, increasing the hydrophobic or charged a.a. content of HLBD10 improved its 
activity.
The kinetics of the microbicidal activity of HLBD1 and a modified a.a. sequence of HLBD10 
(HLBD10opt3, Table 3) showed that the longer a.a. sequence killed C.albicans within 10 min, 
S.aureus within 1 h, and E.coli after 2 hrs (Fig 12 a). A somewhat different pattern was seen 
with the small peptide regarding S.aureus which was killed within 30 min (Fig 12 b).
The differences in the kinetics of killing are probably due to the different cell envelopes of the 
three microorganisms. E. coli has an outer membrane, containing LPS, proteins and 
phospholipids not present in S. aureus. The cell envelope of C. albicans contains 
mannoproteins and polysaccharides. The cytoplasmic membrane of C. albicans is also 
different by containing ergosterol. Theoretically, it would be expected to take more time for a 
peptide to penetrate two membranes as in E. coli.
One of the mechanisms for the killing of E. coli by Lfcin has been suggested to be mediated 
via the binding of the peptide to LPS. Therefore, the most potent peptides were studied for 
their neutralization of the Limulus activity of LPS and lipid A.
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Table 7. Microbicidal activity of the peptides derived from HLBD10 (a. a. 20-31) 
(CFQWQRNMRKVR) by alanine scan. The peptides were incubated for 2 h with E.coli, S. 
aureus, and C. albicans in diluted BH1 medium (BHIdu) or 1% bactopeptone (BP). The 
concentration of peptides needed for 99% killing is shown (MMC 99).
position a.a.
replaced
by
alanine
MMC 99> M-g/ml
E.coli
BHIdil BP
S. aureus
BHIdiI BP
C. albicans
BHIdu BP
20 C >25' >100* 14 >100 12 >100
21 F 12 n.d. 7 n.d. 12 n.d.
22 Q 6 50 3.5 100 6 25
23 w 25 >100 14 >100 12 >100
24 Q 12 50 3.5 100 12 50
25 R 12 n.d. 7 n.d. 12 n.d.
26 N 6 25 3.5 50 6 25
27 M 12 50 3.5 >100 25 50
28 R 25 >100 7 >100 25 >100
29 K 12 100 3.5 >100 25 > 100
30 V 12 50 3.5 >100 25 50
31 R 12 >100 7 >100 25 >100
none 12 100 7 >100 12 50
The small peptides corresponding to a.a. 17-31, 18-31, 19-31, and 20-31 (HLBD7-10) 
inhibited the Limulus activity of lipid A from 60 to 90%. (Fig. 13 a). Using the longer 
peptides HLBD1 and HLBD2, the neutralization effect was at most 30% for the diphosphoryl 
lipid A. The peptide HLBD9 (a.a. residues 19-31) reduced the Limulus activity of 0111 LPS 
to 54 and 055 LPS to 46% (Fig. 13 b). This inhibitory effect was comparable to the LPS 
neutralization agents polymyxin B and BPI.
In summary, this study showed that a 13 a.a. long fragment comprising more than half of the 
antibacterial a helix region in the hLF molecule was the most active microbicidal fragment 
against E. coli, S. aureus and C. albicans, but the 12, 14, and 15 a.a. long fragments were of 
similar activity. The C residue at the N terminal end (position 20), a hydrophobic residue at 
position 23 and the charged a.a. at positions 28 and 31 were important for the antimicrobial 
activity. The 12-15 a.a. long peptides may contribute to the killing of E. coli by binding to 
LPS/lipid A, thereby damaging the integrity of the outer membrane.
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a) b)
HLBD1 HLBD10opt3
S5 100-
.2 20-
5 10 30 60 120
Incubation time, min
E.coli
-o-S.aureus 
-t-C. albicans
55 100-
5 10 30 60 120
Incubation time, min
Fig. 12. Kinetics of the killing activity of the peptides HLBD1 (a) and HLBD 10 opt3 (b). The peptides 
were incubated with E.coli 06K5, S. aureus (1800), and C. albicans in BP for 20 hrs using 200 pg/ml 
of HLBD 1 and 100 pg/ml of HLBD10 opt3. Samples were collected directly after mixing and at 5, 10, 
30, 60, 120 min and 20 hrs. Each point represents the percentage of the inoculum remaining alive.
b)
9 10 tap HLBD1 HLB02
Inhbiting agent (25 ng)
LipidAm UpidAdi 0111LPS 055LPS
■■ HLBD9 
EZ]Polyrryidn 
I IBPI peptide
Fig. 13. Neutralization of the Limulus activity of di- and monophosphoryl lipid A (300 pg/ml) (a) by 
incubation with HLBD peptides (25 ng/ml); and LPS (Olll and 055, 300 pg/ml) (b) by incubation 
with HLBD9, polymyxin B, and BPI peptide (5 pg/ml). (n.d. means not determined).
48
CONCLUDING REMARKS, HYPOTHESES AND EMERGING 
QUESTIONS
The innate immunity at mucosal surfaces plays a crucial role in protection against infection 
and in development and modulation of inflammatory responses. The evolutionary conserved 
factors provided by the secretions at mucosal sites constitute key elements in the first line of 
defense (257). They consist of antimicrobial proteins and peptides that are either 
constitutively expressed or induced in response to infection and inflammation (257). Their 
role in defense is usually a result of the ability to act as antimicrobials, as well as to 
orchestrate the cells of the immune system in the response (257). The role of lactoferrin as a 
factor of innate defense is supported by its presence in high concentration in the mucosal 
secretions, and its antimicrobial and immunomodulatory effects, noted in in vitro studies. 
Since the immune system of the newborn is not fully developed and functional, the support 
provided by the mother for protection at mucosal surfaces is crucial because this is where 
most infections are initiated especially in children (258). It is well documented that 
breastfeeding provides protection against respiratory and urinary tract infections, diarrhea, 
necrotizing enterocolitis, otitis media and septicemia (258, 259). There is also evidence that 
the enhanced protection against certain infections, including UTI can last after the termination 
of breast feeding (258, 260). The defense factors present in milk offer such a protection. The 
most studied component in this respect are the slgA antibodies which are directed against 
microbes that the mother has encountered in her gut previously in life (258).
The role of orally given LF in protection against infection and inflammation at mucosal 
membranes has been poorly explored in vivo. Therefore, the major question addressed in this 
thesis was if anti-infectious and anti-inflammatory activities at the mucosal surfaces could be 
mediated by the orally given LF. The mechanism by which LF down regulates cytokine 
production in monocytes was also addressed by in vitro studies. Our results clearly 
demonstrated that orally given LF is effective in vivo in reducing infection and inflammation 
at a remote site, the urinary tract and mediates anti-inflammatory activities in the colon. The 
dual effects of hLF may at least partly reside in the antimicrobial region of the molecule, 
since we also found synthetic fragments based on this region to be effective in vivo. One of 
the possible mechanisms by which LF mediates its anti-inflammatory effects in vivo could be 
its ability to down regulate pro-inflammatory cytokines at the transcriptional level by 
interference with the NF-kB transcription factor, as we have shown in vitro.
The prerequisite for orally given LF or fragments to exert its biological activities locally at 
mucosal surfaces such as in the urinary tract or the colon, is their ability to reach these sites. 
Using the ELISA method we detected hLF in the serum and urine of animals fed hLF, 
indicating that hLF pass via the circulation and in this way can reach the urinary tract, and in 
addition to the oral route, also the colon. However, to which extent LF or the synthetic 
peptides are degraded during the passage through the intestinal tract was not elucidated in our 
study. Our attempts to identify by electrophoresis and immunoblotting the hLF or its 
fragments in the urine of animals with E. coli urinary tract infection, which received orally 
hLF, were not successful. This was due to the fact that the anti-hLF antibodies cross-reacted 
with the mLF present in the urine of the experimental animals in response to the infection,
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resulting either from the urinary PMN or possibly from secretions. Using a double sandwich 
ELISA, we detected hLF in the urine of uninfected animals fed hLF. However, we do not 
exclude that larger fragments possibly generated by degradation of hLF during the passage 
through the intestinal tract may be a major part in this system of detection. The peptides 
HLD1 and HLD2 did not react in our ELISA method (data not shown). We have also tried to 
detect the peptides HLD1 and HLD2 in the urine of infected animals by mass spectrometry 
and purification on chromatography using beads reported to bind cationic peptides. However, 
the lower sensitivity of the mass spectrometry (>100 ng) and the interference with the host 
defensins (261), present in urine in response to infection and having approximately the same 
molecular weight as HLD1 and HLD2 peptides, made our attempts unsuccessful. The labeling 
of the peptides would be preferable. However, this might very well change the peptide 
conformation, uptake, and possibly binding to the intestinal receptor for hLF. Receptors for 
LF on the brush borders of the small intestine of rhesus monkey and human infant intestine, 
with preference for binding hLF and monkey LF, but not bLF have been reported (262). The 
number of binding sites for the receptor of hLF is higher on the intestine of the suckling than 
older infants (75). Beside the entire hLF molecule, the large fragments corresponding to the N 
terminal lobe of the hLF molecule also bind to the receptor (75). In mice, the intestinal 
receptor binds LF from different species with the same affinity (69, 70). The role of these 
receptors in the uptake of LF in the circulation is not known. LF and large LF fragments have 
been detected by others in the urine and faeces of human infants fed human milk (63, 65, 66, 
263).
To which extent the microbicidal fragment LFcin or even smaller fragments are generated in 
vivo by digestion of LF during its passage through the gastrointestinal tract in humans, 
especially in infants, and in mice is little investigated. In our studies, the synthetic hLF 
fragments were as effective as hLF in reducing the infection and inflammation in the urinary 
tract and the inflammation in the colon. Smaller fragments (12 -15 a.a long) than those used 
in vivo (23-25 a.a. long) were similar or sometimes even better in their killing activity against 
E. coli, S. aureus and C. albicans in vitro. If these fragments are also generated in vivo, as a 
result of degradation of LF or the synthetic fragments in the intestine or at the site of infection 
remains to be determined. It is of interest to explore to which extent active LF fragments are 
generated in vivo, especially in the suckling newborns, who have a lower secretion of gastric 
acids and synthesis of digestive enzymes than older children and adults (264). Would these 
fragments be formed in vivo by enzymatic digestion with matrix proteases that are present at 
mucosal sites in inflammatory conditions, or by proteases secreted by bacteria?
A lower risk of infections in the gut and urinary tract has been observed in breast fed infants 
(258, 259). Our results of an anti-infectious and anti-inflammatory effect of hLF or synthetic 
fragments in the urinary tract may help explain such an observation. Thus, hLF may provide, 
as the slgA antibodies much of the mucosal protection transferred by the mother via the milk 
to the offspring.
hLF or LF fragments may possibly interact with other components of the host defense in 
regulating the antimicrobial activity at mucosal surfaces. A synergy between LF and slgA or 
lysozyme has been described in vitro (96-98, 265).
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The suckling neonate could benefit from the dual antimicrobial and anti-inflammatory 
property of LF or its fragments, especially during the colonization and expansion of the 
intestinal microflora. It is known that there are differences with respect to the predominating 
species in the intestine of breast fed compared to bottle fed infants. Thus, breast fed infants 
have lower counts of clostridia, a tendency to a lower count of enterobacteria, and higher 
counts of staphylococci than bottle fed infants (266-268). hLF together with slgA may 
contribute to the colonization pattern of the gut by limiting the number of colonizers and 
protecting against pathogen invaders in the period when the infant still has a somewhat 
immature immune system of its own.
Our results also showed the ability of LF to down-regulate LPS-induced pro-inflammatory 
cytokines in monocytic cells. An activation of the cellular innate system of the infant by the 
new colonizers carrying LPS and resulting in pro-inflammatory cytokines, could be down 
regulated by hLF. TNF-a was found to be the most down regulated cytokine by LF in our in 
vitro system.
TNF-a is a potent pro-inflammatory cytokine and induces the expression of adhesion 
molecules on the endothelial cells, fever, the secretion of other pro-inflammatory cytokines 
such as IL-1 and IL-6, and is thus an important mediator of inflammation, septic shock and 
certain inflammatory diseases e.g. rheumatoid arthritis (138). The down regulation of this 
early pro-inflammatory cytokine by LF in the gut may prevent a strong inflammation with 
consequences for the integrity of the gut mucosa.
In our in vitro system we noted the down regulation by LF of also TNF-a and IL-lß-induced 
cytokines. We suggest that one possible mechanism for the down-regulation of the 
proinflammatory cytokines is through interference with their common gene regulator, the 
transcription factor NF-kB. This finding may have potential therapeutic use. NF-kB is known 
to be important in the pathogenesis of many diseases such as IBD, rheumatoid arthritis, 
diabetus, and thus a therapeutic target (269).
Since LF was found intracellularly in monocytic cells, we do not exclude, however, and it 
remains to be determined, if it may interfere with other signal transduction pathways leading 
to proinflammatory cytokines, such as MAPKases. The exact mechanism of LF interference 
with NF-kB needs also to be elucidated. Whether LF binds to NF-kB in the nucleus, if the 
possible NF-kB-LF complex is transported to the nucleoli where we find LF in the cells, are 
open questions.
In addition to increasing our knowledge about the role of LF as an important element of the 
innate defense at mucosal surfaces, the anti-infectious and anti-inflammatory activities of LF 
and fragments thereof may possibly be of potential therapeutic value.
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